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Introduction 
According to Finnish population studies, approximately 
400 000 Finnish patients suffer from chronic bronchitis 
(Hunti and Ikkala, 1980; Keistinen et al., 1996). Approxi- 
mately one-half suffer from chronic obstructive pulmonary 
disease (COPD). The number of patients with COPD is 
underestimated by diagnosis and is increasing. The treat- 
ment of these patients in Finland requires more hospital 
treatment days than the treatment of asthma. 
The most serious risk factor for COPD is smoking, 
especially if it has started at a young age, has lasted for a 
long period of time and use is heavy (Peto et al., 1994; Peto, 
1996). Approximately one-half of smokers develop symp- 
toms of chronic bronchitis and one-fifth develop COPD 
(Peat et al.; 1990). A slow progression is typical of COPD. 
In the early stages the patient is symptomless, therefore it 
is very hard to recognize the disease at this stage when 
treatment would be easy. 
According to the National COPD Guidelines for Preven- 
tion and Treatment, the main responsibility is in public 
health care, which is supported by pulmonary specialist 
care. The main prevention strategy for COPD should focus 
either on patients with symptomatic chronic bronchitis or 
even before symptoms appear in those at risk, for example 
because of smoking (Linden et al., 1993). 
The national programme has the following goals: 1. a 
decrease in the incidence of chronic bronchitis; 2. recovery 
by the greatest possible number of chronic bronchitis 
sufferers; 3. the maintenance of good working and general 
ability in COPD sufferers; 4. a decrease in the proportion of 
moderate and serious COPD sufferers; 5. an overall 
decrease of 25% in hospitalization due to COPD; and 6. a 
decrease in annual costs per patient. The most important 
measures towards achieving these goals include: 1. reducing 
smoking; 2. reducing occupational and outdoor pollutants 
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and improving indoor air quality; 3. increasing conscious- 
ness in risk groups of risk factors and improved treatment; 
4. early diagnosis and active treatment, particularly of 
smokers; 5. the development of supervized self-treatment; 6. 
early, individually planned rehabilitation carried out as part 
of treatment; and 7. encouragement of research into these 
diseases. 
The main target of treatment is for the patient to stop 
smoking (Anthonisen et al.; 1994; Henningfield: 1995). 
Bronchodilating drugs (anticholinergic agents, short and 
long-acting /&-agonists) and theophylline medication are 
used to treat symptoms (Siafakes et al., 1995). Long-acting 
/&-agonists seem to have a slower but longer-lasting effect 
than anticholinergic drugs. The use of inhaled corticoster- 
oids in COPD is increasing (Pauwels et al.; 1999), especially 
if there is some degree of concomitant airway reversibility 
and/or inflammation. We anticipate the development of 
new drugs with different mechanisms of action in COPD. 
Foreword 
The annual costs of COPD are estimated at FIM 5 billion. 
The foundation for the construction of a national preven- 
tion programme rests on the seriousness of the effects on 
national health and the economy, the increased knowledge 
of preventative measures and treatment possibilities, and 
synergy with the national asthma programme. 
At the beginning of 1996, the Finnish Lung Health 
Association, Finnish Association of Specialists in 
Pulmonary Medicine, Association of the Pulmonary 
Disabled, and professors in pulmonary medicine from the 
universities of Helsinki. Kuopio, Oulu, Tampere and Turku 
suggested to the Finnish Ministry of Social Affairs and 
Health that a Workgroup be set up to prepare a national 
COPD prevention and treatment programme. Initial inves- 
tigations and programme outline planning were carried out 
by The Finnish Lung Health Association with funding 
allocated by the Finnish Ministry of Social Affairs and 
Health under the Tobacco Act. 
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Management of the preparation of the chronic bronchitis 
and COPD prevention and treatment programme 199% 
2007 is in the hands of the board of the Finnish Lung 
Health Association. The board members are Professor 
Lauri A. Laitinen (Chairman), Jaakko Jylha, Chancellery 
Counsellor, Ritva Kauppinen, Chief Physician, Eeva-Liisa 
Moilanen, LL.M, Professor Markku Nieminen, Professor 
Erkki 0. Terho, and Juhani Torma, Financial Director. 
Emeritus Professor Eero Tala has acted as a permanent 
expert advisor. The practical preparations and writing of 
the programme have been the responsibility of Rauni 
Ruohonen, Specialist Physician, and Kaj Koskela, 
Secretary General. 
The Finnish Medical Society Duodecim’s language com- 
mittee considered the Finnish Lung Health Association’s 
proposed term chronic obstructive pulmonary disease 
(COPD) to be appropriate, and so this has been used in the 
programme. 
During preparation, the following experts were con- 
sulted: Antti Ahonen, Medical Director, Laakso Hospital; 
Eeva Ahonen, Chief Physician, Espoo Health Centre; Tari 
Haahtela, Chief Physician, Skin and Allergy Hospital; 
Kaija Hasunen, Special Advisor, Ministry of Social Affairs 
and Health; Emeritus Professor Esko Huhti; Jussi 
Huttunen, Director, National Public Health Institute; Paivi 
Hamalainen, Project Physician, Neighbourhood Health 
Care Association; Maritta S. Jaakkola, Specialist Phys- 
ician; Kaisu Juntunen-Backman, Assistant Chief Physician, 
Skin and Allergy Hospital; Timo Keistinen, Director Chief 
Physician, Central Ostrobothnia Health Care Region; Pro- 
fessor Vuokko Kinnula, Oulu University Hospital; Timo 
Klaukka, Consultant Physician, Social Insurance Institu- 
tion, Heikki J. Korhonen, Deputy Senior Physician, the 
Cancer Society of Finland; Jyrki Kotaniemi, Senior Phys- 
ician, LHnsi-Pohja Central Hospital; Paula Kuusisto, 
Deputy Chief Departmental Physician, Tampere University 
Hospital; Seppo Miilunpalo, Specialist Researcher, UKK 
Institute; Margit Pelkonen, Research Assistant, University 
of Kuopio; Anne Pietinalho, Chief Physician, Lansi- 
Uusimaa Regional Hospital; Matti Rauhalahti, Researcher, 
National Public Health Institute; Paavo Rissanen, Consult- 
ant Physician, Social Insurance Institution; Yrjii Salorinne, 
Chief Physician, Helsinki Health Department, Clinical 
Physiology Unit; Professor Anssi Sovijarvi, Helsinki 
University Central Hospital; Senior Lecturer Seppo 
Sutinen; Senior Lecturer Heikki Tala; Professor Hannu 
Tukiainen, Kuopio University Hospital; Pentti Tukiainen, 
Chief Departmental Physician, Helsinki University Central 
Hospital; Kari Venho, Chief Physician, Central Finland 
Health Care Region; Sirkku Vilkman, Deputy Chief 
Physician, Porvoo Hospital, Uusimaa Health Care Region; 
Acting Assistant Professor Ilkka Vohlonen, University of 
Helsinki; and Professor Ilkka Vuori, UKK Institute. 
Statements regarding the programme have been received 
from: the Ministry of the Environment, Social Insurance 
Institution, National Public Health Institute, Institution of 
Occupational Health/Finland, Slot Machine Association 
(RAY), Southern Finland County Administrative Board, 
Lapland Health Care Region, Tampere City Department of 
Social Services and Health Care, Vaasa Health Centre, 
Asthma 1 Airflow obstruction 
FIG. 1. Diagram of chronic obstructive pulmonary 
disease. 
Finnish Medical Association, Finnish Dental Association, 
Association of Finnish Pharmacies, Finnish Association of 
Municipal Doctors, National Union of Public Health 
Nurses, Finnish Centre for Health Promotion, Finnish 
Allergy and Asthma Association, Association of the 
Pulmonary Disabled, Samfundet Folkhalsan rf., Finnish 
Association of Specialists in Pulmonary Medicine, Finnish 
Association of Clinical Physiology, and Neighbourhood 
Health Care Association. The National Health Commis- 
sion appointed by the Finnish Government has reviewed 
the programme. 
The overall national programme is a recommendation for 
the prevention and treatment of chronic bronchitis and 
COPD. The rapid development of medical science, and 
particularly medical treatment, makes periodic review of 
the programme essential. Responsibility for treatment 
belongs to the individual patient and the healthcare profes- 
sional and unit treating the patient. The programme is 
based on results from numerous studies, investigations, and 
practical experiences. The text does not provide detailed 
references to the literature, but an appendix of the most 
important sources is provided. 
The Ministry of Social Affairs and Health hopes that the 
programme will form a useful tool in the prevention of 
chronic bronchitis and COPD. 
JARKKO ESKOLA 
Director-General 
Finnish Ministry of Social Affairs and Health 
Public health and financial perspectives 
DEFINITIONS 
Pulmonary disease associated with lower airways obstruc- 
tion is classified as chronic obstructive pulmonary disease 
(COPD) or asthma, on the basis of the clinical picture. 
COPD covers at least three factors: chronic bronchitis, 
emphysema and progressive obstruction of the small 
airways (Fig. 1). 
Chronic bronchitis is defined as chronic production of 
mucus in the lungs for at least 3 months during at least 2 
consecutive years, with no other underlying pulmonary or 
cardiac disease. Chronic bronchitis can occur with or 
without airways obstruction. 
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FIG. 2. Course of chronic obstructive pulmonary disease. 
Chronic obstructive yulmonayy disease (COPD) is char- 
acterized by slowly progressing, mainly irreversible airways 
obstruction and a decreased expiratory flow rate. The 
decreased flow rate is caused by varying degrees of airways 
obstruction and emphysema. 
Emplzysenza is defined as permanent enlargement of the 
air spaces distal to the terminal nonrespiratory bronchioles, 
primarily the alveolar area, without obvious fibrosis. 
Asthma is an inflammatory disease of the bronchial 
mucosa usually associated with varying degrees of 
bronchial obstruction, which subsides either spontaneously 
or in response to therapy. Specific characteristics of asthma 
and measures for improvement of the prevention and 
treatment of asthma are discussed in the National Asthma 
Programme for 19942004. 
As far as the course of disease is concerned, chronic 
bronchitis is preceded by a phase of bronchial symptoms 
occurring in connection with, e.g., respiratory infections, 
exercise or exposure to allergens. In most individuals 
symptoms subside rapidly. Symptoms are considered pro- 
longed if they persist for over 6 months. These conditions 
may become even more chronic. Some patients with 
chronic bronchitis develop COPD. This involves disorder 
of the small airways associated with varying degrees of 
emphysema. COPD can however sometimes result from 
emphysema with associated development of abnormalities 
in the small airways (Fig. 2). 
The course of the disease can best be controlled during 
the initial phase, least well during the final phase. To 
achieve the goals set for this programme and for prevention 
of the disease it is vital to focus on preventative measures, 
early diagnosis, and intensive treatment of the disease at 
an early stage. 
PATHOPHYSIOLOGY 
The lower airways are divided into conductive airways (the 
trachea and bronchi) and gas-exchanging airways (alveoli). 
The most important changes in COPD occur at the margins 
of these areas, where small, membrane-like bronchioles 
become respiratory bronchioles and branch into alveolar 
ducts. Small bronchiolar walls have no cartilage. The 
bronchioles remain patent through support by the walls of 
the surrounding alveoli. 
The inner surface of an alveolus is covered by a sur- 
factant phospholipid membrane secreted by epithelial cells. 
In healthy individuals, this membrane continues at least up 
to bronchiolar level. The phospholipid membrane, epi- 
thelial cells and tight capillary network form the alveolar 
wall, supported by elastic fibres. The surfactant membrane 
itself is also an important alveolar support structure. 
Mucous glands in the bronchi secrete a mucous layer onto 
the membrane, and this layer is moved towards the trachea 
and larynx by epithelial cilia. Macrophages, lymphocytes, 
and protease inhibitors and antioxidants derived from 
circulating blood protect the most peripheral airways 
against microbes, allergens and chemical hazards. In 
healthy individuals, alveoli contain very few neutrophilic 
leukocytes. 
Early stage 
External irritants such as cigarette smoke cause bronchial 
reactions that vary from one individual to another. The 
cause of the reaction resulting in chronic bronchitis and the 
cause of development of asthma have not yet been 
established. 
The mucosal surface in large airways is damaged, result- 
ing in swelling of the internal structures and accumulation 
of inflammatory cells on the mucosa. The distribution and 
level of activity of inflammatory cells differ from those 
present in asthma, and the cells are often inactive. 
Cigarette smoke reduces the surface tension of the phos- 
pholipid membrane and increases the numbers of macro- 
phages and neutrophilic leukocytes in alveoli and 
respiratory bronchioles. Enzymes secreted by neutrophils, 
and, to some extent, by macrophages, against microbes 
begin to break down the elastic fibres of the alveolar walls. 
At the same time oxidants in cigarette smoke inactivate 
factors protecting the elastic fibres, such as alpha, anti- 
trypsin. This is how destruction of alveolar walls surround- 
ing bronchioles, i.e. emphysema, begins simultaneously 
with the chemical inflammation and small airways disease. 
Symptomatic disease 
Chronic bronchitis is a disorder of the large airways associ- 
ated with cough and production of sputum, As a result of 
epithelial damage, ciliated cells are replaced by mucus- 
secreting goblet cells or, in the case of prolonged damage, 
by squamous epithelium. This impairs elimination of 
mucus. Concomitantly, inflammatory cells accumulate in 
the subepithelial mucosa, and mucous glands become 
enlarged and their number increases. This results in an 
increase in the amount of viscid mucus. The ability of 
mucous glands to excrete antibacterial enzymes is impaired 
and susceptibility to bacterial infection is increased. 
Bronchial smooth muscle sometimes also increases. Con- 
comitant inflammatory changes of varying degrees occur in 
the small airways. 
In COPD, the most important changes occur in small 
airways with diameters smaller than 2 mm (bronchioles). 
These are essential for oxygen intake. Small airways 
become obstructed if their walls thicken as a result of 
inflammation, or they collapse during expiration because of 
loss of pulmonary tissue surrounding the airways as a 
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consequence of emphysema. Prolonged inflammation leads 
to development of fibrous scarring beneath the mucosa and 
tissue loss. Loss of sites of attachment of bronchioles and 
alveoli leads to kinking of the airways and variation in their 
diameters. Smooth muscle thickening increases airways 
obstruction. 
In emphysema, alveoli are destroyed, elasticity is lost and 
the capillary network responsible for oxygen transportation 
is reduced. The extent and severity of emphysema are the 
most important factors affecting the course of and prog- 
nosis in COPD. Small airways abnormalities alone are not 
likely to cause severe respiratory depression. When small 
airways abnormalities and emphysema co-exist, the 
ventilation/perfusion ratio is adversely affected: there is 
ventilation of non-perfused parts of the lung and perfusion 
of non-ventilated areas, which results in further reduction 
of oxygenation. 
If smoking is discontinued before symptoms occur, the 
inflammatory reaction ceases or diminishes. Once COPD 
has progressed to a stage at which there are severe symp- 
toms, discontinuation of smoking will not result in any 
significant reversal of structural damage but deterioration 
of lung function will be retarded, and symptoms will 
decrease. 
Degt-ees of severity 
Significant airway obstruction is defined as a condition in 
which the ratio of forced expiratory volume in 1 s to vital 
capacity (FEVJVC) is less than 88% of the reference value 
(Viljanen et al., 1982) (ERS 1995). On the basis of inter- 
national and recent Finnish epidemiological and clinical 
data, a rough estimate is that 60% of patients suffering from 
chronic bronchitis will have no airway obstruction but 40% 
will have developed COPD. 
In terms of public-health workload, COPD can be 
divided into the following three groups, according to its 
degree of severity: 
(1) Mild disease, often without symptoms and undetected 
(75% of patients); 
(2) Moderate disease, requiring medical treatment (20% of 
patients); 
(3) Severe disease, requiring annual hospital treatment (5% 
of patients). 
On the basis of severity of airways obstruction, COPD 
can be divided into three groups, according to FEV, and 
mid-expiratory flow (MEF,,). The classification is based on 
distribution of FEV, and MEF,, values in healthy non- 
smokers in the reference-value material of Viljanen et al. 
TABLE 1. Degrees of severity of COPD 
Mild FEV, ~80% and/or MEF,, ~62% of reference 
value 
Moderate FEV, 165% and/or MEF,, ~35% of reference 
value 
Severe FEV, ~45% of reference value 
TABLE 2. Prevalences of chronic bronchitis by sex and 
region according to the Mini-Suomi study 
Region 
Men Women 
(%I (%I 
South-west Finland 18.5 5.7 
South Finland 16.6 6.3 
West Finland 18.5 6.9 
East Finland 24.2 6.7 
North Finland 25.3 8.2 
(1982). The limit for mild change is the lower limit of the 
95% confidence interval (2 SD lower than the reference 
value). The limit for moderate change is 3.5 SD and the limit 
for severe change 5.5 SD lower than the reference value 
[Reference values: Viljanen et al. (1982); classification: A. 
Sovijgrvi et al. (1994)] (Table 1). 
OCCURRENCE 
Prevalence 
Chronic bronchitis and COPD are common in the indus- 
trialized world, particularly in men. Chronic bronchitis/ 
COPD is the fifth commonest chronic disease in the world. 
In developing countries, the risk factors for and prevalence 
of the disease differ from those in industrialized countries, 
the disease being commoner in women than in men. It has 
been estimated that only about 25% of cases are detected in 
industrialized countries. In developing countries the figure 
is considerably lower. Examples of international rates of 
occurrence of chronic bronchitis and COPD are given in 
Appendix 1. 
In the Mini-Suomi study, conducted by the Finnish 
Social Insurance Institution from 1978 to 1981, the preva- 
lence of chronic bronchitis increased with age in men over 
30 years of age from 15 to 27% and the prevalence of 
COPD from 2 to 19%. In women, prevalence and effects of 
age on prevalence were lower, from 5 to 8% and 1 to 8%, 
respectively. There are regional differences in prevalences of 
chronic bronchitis (Table 2). The differences probably 
largely relate to differences in smoking habits. A cold 
climate may increase the adverse effects of smoking. 
According to a recent FinEsS study (an international 
epidemiological respiratory survey performed in Finland, 
Estonia and Sweden), 10% of the adult population in 
Lapland had chronic bronchitis, and COPD occurred in 
50% of these patients. In addition, 8-10% of the population 
had latent, undiagnosed COPD. The prevalence of chronic 
bronchitis increased with age, from 7 to 13% in men and 
from 5 to 12% in women over 20 years of age. The recent 
data suggest that prevalence in men is decreasing and that 
in women is approaching the figures observed in men. 
The prevalence of chronic bronchitis in Finnish children 
is estimated to be between 2 and 4%. In the elderly, the 
prevalence of COPD is considerably higher than that 
suggested by the number of cases detected. Almost 50% of 
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FIG. 3. Prevalence of COPD in the population over 65 
years of age by sex (w, diagnosed; 0, undiagnosed). 
cases in the elderly remain undiagnosed (Fig. 3). Most 
suffer from mild to moderate COPD. One-third of patients 
suffer from severe dyspnoea resulting in their seeking 
medical attention. 
The aging of the population, especially now that the 
baby-boom generation is reaching old age, is increasing 
prevalences of both chronic bronchitis and COPD. 
Improved treatments also increase the life expectancies of 
patients. On the other hand, the reduction of smoking 
in men reduces the occurrence of new cases. In future, 
incidence will be affected by increases in smoking, in 
adolescents and women in particular. 
Applied in proportion to the Finnish population as a 
whole, the results of the Mini-Suomi study suggest that 
there are 400 000 individuals in Finland with chronic 
bronchitis, of whom at least 175 000 have symptomatic 
COPD. On the basis of the results of the study conducted in 
Lapland, the number of individuals with latent COPD may 
be even double the number of cases of symptomatic COPD. 
On the basis of smoking statistics, there would appear to be 
over 200 000 patients suffering from COPD. 
Moufalify 
In 1996, COPD was the fifth commonest cause of death in 
the world. It is estimated that it will become the third 
commonest cause of death by 2000. There are marked 
differences in mortality from COPD between countries. 
Some of the differences may be associated with differences 
in risk factors, some with differences in practices relating to 
the complilation of death certificates. Mortality has 
increased in many countries since the 1960s. However: in 
many industrialized countries, mortality in men has 
decreased, mainly as a result of decreased smoking. Mor- 
tality in women over 55 years of age is on the increase. In 
European mortality statistics, Finland is approximately in 
the middle. 
In Finland, 750-1000 individuals die from COPD 
annually. According to the East-West Study, patients with 
COPD die from lung cancer more frequently than others, 
and from heart disease at a younger age than others. Men 
outnumber women in mortality statistics by five to one. 
Mortality is greatest in the 70-85 years age group. 
Mortality decreased in the 1970s and 1980s in almost all age 
groups. However, in the past few years, mortality in women 
has increased, in the 65575 years age group in particular 
(Fig. 4). 
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FIG. 4. Mortality from COPD per 100 000 inhabitants in 
Finland from 1955 to 1993, by sex (A, men; @, women). 
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FIG. 5. Actual (---) and predicted (. .) numbers of 
hospitalization days from COPD from 1972 to 2020, by 
sex. 
Hospital workload 
In 1972, the number of COPD-related hospitalizations in 
Finns over 34 years of age was 123 000 (60.6 days per 1000 
inhabitants). In 1994 the corresponding figure was 119 000 
days (43.0 days per 1000 inhabitants). The average length of 
stay fell during this period, from 16 to 9 days. 
According to a forecast based on change in age structure, 
treatment periods and hospitalization days may increase by 
the year 2010 by up to 55% for men and 12-24% for 
women, compared to the current situation. By the year 
2020, hospitalization days for men could increase by up to 
94% (Fig. 5). However, the actual increase in hospital- 
ization is likely to be somewhat smaller than that indicated 
by the forecast as smoking in men has decreased since the 
1970s. 
There appear to be substantial regional differences in the 
organization of treatment. In some hospital districts, 
patients with COPD account for a relatively small pro- 
portion of hospitalizations. In others they account for a 
substantial proportion of the hospital workload. 
Outpatient-care workload 
There are no exact data on annual numbers of outpatient 
visits as a result of chronic bronchitis and COPD. Patients 
with mild COPD (approximately 130 000 individuals) seek 
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TABLE 3. Risk factors for chronic bronchitis and COPD 
Degree of 
certainty Environmental factors Host factors 
Established Cigarette smoking 
Some occupational exposures 
a,-antitrypsin deficiency 
Good evidence Air pollution (particularly SO, and particulates) Low birth weight 
Poverty, low socio-economic status Atopy (high IgE) 
Alcohol Bronchial hyperresponsiveness 
Environmental tobacco smoke in childhood Family history 
Other occupational exposures 
Reproduced with permission from Siafakas et al. (1995). 
outpatient medical attention because of respiratory infec- 
tion and production of mucus between one and four times 
per year. Patients with moderate COPD (approximately 
35 000) visit a specialist two to three times per year during 
the initial stage of the disease. In outpatient departments 
for pulmonary diseases, patients with COPD account for 
lo-20% of outpatient visits overall, depending on the 
hierarchy of health services. In addition to requiring medi- 
cal attention, patients need considerable amounts of guid- 
ance and advice from other health-care staff. They pay from 
one to four visits to public-health nurses annually. Patients 
with severe COPD (approximately 10 000) require continu- 
ous monitoring and medication. Ten per cent (approxi- 
mately 1000 patients) receive long-term oxygen therapy at 
home. These patients require hospital and outpatient 
services the most. Specialized health-care workers visit 
patients on oxygen therapy one to three times a year, in 
addition to visits by patients to outpatient clinics. In 
summary, it is estimated that nearly one million outpatient 
visits are paid annually because of chronic bronchitis and 
COPD. 
CAUSES AND RISK FACTORS 
Chronic bronchitis and COPD are caused by environmental 
factors and host-related factors (Table 3). 
Host factors 
a,-antitrypsin deficiency is a hereditary metabolic disorder, 
the commonest manifestation of which is development of 
severe emphysema at young age. Sixty per cent of patients 
develop symptoms under the age of 40 years. Some patients 
with a,-antitrypsin deficiency are at risk for COPD. In 
Finland, the number of individuals of ZZ phenotype suf- 
fering from a,-antitrypsin deficiency is estimated to be 
1000. 
Birth weight has been found to affect FEV, in adulthood. 
If birth weight is low, FEV, will also be low. Development 
of the bronchi ends during the 16th week of gestation; 
development of the alveoli primarily at age 2-3 years. Early 
foetal disorders affect the bronchi and later disorders the 
alveoli. Reduction in airways will always limit the number 
of subsequent alveoli, and there cannot therefore be 
compensation later for early disorders. 
Respiratory infections before age 12 months (severe 
pneumonia, bronchiolitis and whooping cough) may impair 
pulmonary function later in life, and predispose to obstruc- 
tive lung disease. Infections of the lower respiratory tract in 
early childhood are commoner in individuals with low birth 
weight than in other individuals. 
Reduced pulmonary function is detectable several years 
after pneumonia or other lower respiratory infection in 
adulthood. However, such infections have not been found 
to cause decreases in FEV,. Antibodies to pulmonary 
chlamydial infections are markedly more frequent in severe 
COPD and in men, than in mild COPD or in women. 
However, the role of chronic chlamydial infection in the 
pathogenesis of the disease remains unclear. 
Atopy may be an endogenous factor predisposing to 
chronic bronchitis, COPD and asthma. In Finnish farmers, 
chronic bronchitis has been found to be twice as common in 
atopic individuals than in non-atopic individuals, irrespec- 
tive of smoking. An analysis based on Finnish twin registry 
data also suggests that atopy may be a risk factor. How- 
ever, international findings are conflicting. In many studies, 
no connection between atopy and COPD has been found 
when asthma patients have been excluded from the 
material. 
COPD is often associated with increased bronchial 
reactivity. However, structural changes in the airways may 
themselves result in hyperreactivity, which may be further 
increased by inflammation. Increased reactivity can there- 
fore be a result of anatomical changes caused by the disease 
as well as a risk factor for development of the disease. 
Smoking-related diseases have been found to run in 
families, suggesting hereditary susceptibility to adverse 
effects of smoking. ABO blood group and genetically deter- 
mined ability to secrete ABO antigens into body secretions 
have been studied as possible contributing factors. 
Environmental factors 
Smoking is the most important factor causing COPD. It 
delays normal development of lung function in children 
and accelerates deterioration of lung function in adults 
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FIG. 6. Effects of smoking (FEV,) (-- , sensitive 
smoker; - - -, insensitive smoker; ., ex-smoker; 
-. - non-smoker). Reproduced with permission from 
Fletche; (1977). 
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FIG. 7. Cumulative incidence of COPD in men on the 
basis of the 1959 smoker grouping (East-West study) 
(0, non-smokers; A, ex-smokers; +, smokers). Personal 
communication from Pelkonen. 
(Fig. 6). Fifty per cent of smokers exhibit symptoms of 
chronic bronchitis, and one (sensitive smoker) in five 
develops COPD. In individuals who have stopped smoking, 
the incidence of chronic bronchitis and risk of COPD 
decrease in 10 years to the levels observed in non-smokers 
(Fig. 7). 
As far as mortality from COPD is concerned, 80-90% of 
cases are attributed to smoking. In 1996, 27% of men and 
18% of women over 14 years were smokers (Fig. 8). 
The working environment affects the incidence of chronic 
bronchitis. Quartz, asbestos, wood dust and fluorides are 
important predisposing factors. In some studies, associ- 
ations have been found between sulphur dioxide, metal 
gases, aluminium, glass wool and high temperature and 
chronic bronchitis. In addition to work in iron or steel 
foundries, welding and textile work, risky work includes 
farming and handling of grain. Cadmium has been found to 
cause emphysema. Exposure to dust is associated with a 
greater risk than exposure to gases or smoke. 
In Finland, the prevalence of chronic bronchitis is three 
times higher in farmers than in the rest of the population, 
even though they smoke less. The prevalence is higher in 
animal husbandry than in grain husbandry. Handling of 
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FIG. 8. Proportion of 15-64-year-old daily smokers in 
1960-1996, by sex (---, men; - - -, women). 
Reproduced with permission from Ministry of Social 
Affairs and Health (1996). 
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FIG. 9. Prevalence of COPD in the population over 65 
years of age, according to exposure to work-related dust 
and smoking habits (w, work-related exposure; 0, no 
work-related exposure). Reproduced with permission from 
Isoaho et al. (1994). 
grain used for feed seems to be associated with the highest 
risk. Farming also involves other air pollutants that may 
affect development of chronic bronchitis, e.g. fumes, gases, 
moulds: bacteria, animal epithelium and endotoxins. 
Individuals with farmer’s lung have been found to have 
bronchial obstruction. Over 20% of such individuals 
develop emphysema. 
Evidence of the importance of exposure to work-related 
irritants in relation to development of COPD is increasing. 
The effects of such exposure are evident indirectly in the 
population aged 65 years or over (Fig. 9). 
Air pollutants and a cold climate are known to aggravate 
symptoms of chronic bronchitis and COPD. Increases in 
levels of sulphur and nitrogen oxides in the air markedly 
increase hospitalizations, with a delay of I-3 days. High 
ozone levels also increase symptoms. In cold, dry air even 
low levels of irritants can have adverse effects on the 
bronchi. Outdoor air pollution has decreased in Finland 
during the past few years and is expected to decrease 
further. 
As far as indoor air pollutants are concerned, the most 
important risk factor for COPD is exposure to cigarette 
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smoke in the environment, or passive smoking. More 
information about the roles of airborne microbes such as 
moulds and bacteria in the pathogenesis of chronic bron- 
chitis and COPD is expected to become available soon. 
Recent investigations have revealed that damage caused by 
moisture and moulds, and poor quality of indoor air is 
very common in Finnish buildings, including schools and 
day-care centres. 
Morbidity and mortality from COPD are higher in the 
lower social classes than in the upper social classes. Adverse 
effects of smoking, and exposure to work-related risk 
factors and impurities in indoor air accumulate in indi- 
viduals and families belonging to the lower social classes. 
The effects of poverty on nutritional status may contribute 
to susceptibility to infection and development of the lungs 
in infants and children. Preventive education and health 
services do not reach the lower social classes to the same 
extent as they reach upper social classes. Decreased func- 
tional ability associated with COPD can also lead to social 
regression of a patient. 
Heavy drinking increases chronic bronchitis and impairs 
lung function. The effects of alcohol and smoking are 
synergistic. Drinking also has an effect via other risk 
factors, such as social regression. The consumption of 
alcohol in Finland overall is about average for industrial- 
ized countries. Drinking habits have changed only little 
over the past few decades. According to a study on drinking 
habits conducted in 1992, 22% of men and 5% of women 
between 15 and 69 years of age (approx. 400 000 indi- 
viduals) could be classified as risk consumers, and 200 000 
individuals as heavy drinkers. 
In addition to foetal malnutrition, smoking by a mother 
can play an important part in foetal pulmonary develop- 
ment. Forced vital capacity, which reflects alveolar status, is 
affected by passive smoking, respiratory infection during 
infancy and weight at age 12. months. It would therefore 
seem to be programmed during infancy. 
COSTS 
Direct and indirect costs related to chronic bronchitis and 
COPD result in substantial losses to the public economy. 
Direct costs most commonly arise from use of health 
services and medicines, changes required in working 
environments, and health education directed towards 
patients and the population as a whole. Indirect costs are 
associated with loss of working efficiency and capacity for 
work, sick leave, restrictions on daily functional abilities 
of patients, and adverse social and psychological effects. 
Indirect costs are higher than direct costs. 
Most direct costs relate to hospital treatment of patients 
with severe COPD. There are approximately 175 000 
patients with COPD in Finland. Five per cent (10 000 
patients) suffer from severe COPD and symptoms requiring 
hospital treatment annually. Half of these patients are 
entitled to special reimbursement (75%) for prescriptions 
for medicines, and 10% use oxygen-concentrator therapy at 
home. Annual costs of treatment can be as high as 
FIM 85 000 per patient. Terminal care costs on average 
FIM 65 000 per patient (Salo and Pekurinen, 1996). Some 
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FIG. 10. Annual treatment costs of COPD according to 
severity of disease. 
20% of patients (35 000) have moderate COPD. Because of 
their symptoms, these patients require regular monitoring 
and advice, and hospital treatment from time to time. 
Reimbursement for prescriptions of medication for symp- 
toms is usually 50%. Annual treatment costs in this group 
are roughly FIM 7000 per patient. Approximately 75% of 
patients (130 000) suffer from mild COPD. Mild forms of 
the disease do not give rise to regular hospital or medicine 
costs. Patients visit occupational health services, health 
centres or private practitioners because of respiratory infec- 
tions and are often prescribed antibiotics, as well as cough 
mixtures and sick leave. Annual treatment costs per patient 
are FIM 1000, on average. It is difficult to assess the impact 
of the disease on work efficiency and its contribution to loss 
of work. 
Chronic bronchitis without airways obstruction occurs in 
approximately 220 000 individuals. Costs in terms relating 
to the national economy result primarily from visits to 
doctors, courses of antibiotics, and preventive measures 
such as education about smoking and measures to improve 
dusty environments. The costs are also shared with other 
disease groups, such as asthma and heart disease. Annual 
treatment costs in this patient group are estimated to be 
FIM 200 million. 
Total costs of chronic bronchitis and COPD in Finland 
are some FIM 5000 million. Treatment costs account for 
approximately FIM 1500 million. Indirect costs are esti- 
mated to be roughly 3-3500 million. The distribution of 
treatment costs according to degree of severity of COPD is 
shown in Fig. 10. 
According to a recent Finnish investigation, lifetime 
treatment costs related to COPD are FIM 160 000 per 
patient, at current prices (Salo and Pekurinen, 1996). Treat- 
ment is more expensive than treatment of other tobacco- 
related diseases such as lung cancer and coronary heart 
disease. On the other hand, loss of production is less than 
for other tobacco related diseases. If patients with COPD 
stopped smoking treatment costs would be expected to 
decrease significantly (Fig. 11) (Salo and Pekurinen, 1996). 
Costs will increase in the near future unless prevention of 
these diseases improves substantially. An estimate of costs 
of COPD-related hospitalization illustrates the trend. In 
1994, costs of hospitalization days were FIM 178 million. 
According to an estimate based on aging of the population, 
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FIG. 11. Expected life-time costs (W) caused by smoking- 
induced COPD and savings (0) achievable if smoking 
were stopped in men by age. Reproduced with permission 
from Salo and Pekurinen (1996). 
costs of hospitalization of patients with severe COPD could 
rise to FIM 280 million in 15 years. How matters develop 
depends essentially on the age at which smokers are made 
to stop smoking, and on how successfully smoking among 
adolescents can be prevented. 
Goals of prevention and treatment 
The goals of prevention and treatment for chronic bron- 
chitis and the COPD and rehabilitation of patients from 
1998 to 2007 are shown in Table 4. The most important 
measures for achievement of these goals are recorded in 
Table 5 and discussed in detail in the following sections. 
Prevention of development and 
exacerbation of the disease 
PREVENTION 
The risk of development of the disease can be reduced 
through measures aimed at changing the health behaviour 
of individuals and avoiding environmental exposure 
(primary prevention) and stepping up early diagnosis and 
initial treatment (secondary prevelztion). Correct timing and 
appropriate targeting of rehabilitation can help reduce the 
handicap caused by the disease to individuals (tertiary 
prevention) (Tables 6, 7 and 8). 
TABLE 4. Goals for prevention and treatment of chronic bronchitis and COPD and rehabilitation of 
patients 
(1) Decrease in occurrence of chronic bronchitis 
(2) Recovery of as many patients as possible with chronic bronchitis 
(3) Maintenance of capacity for work and functional capacity of patients with COPD 
(4) Reduction in the percentage of patients with moderate to severe COPD 
(5) Twenty-five per cent decrease in number of days spent by COPD patients in hospital 
(6) Decrease in annual costs per patient 
TABLE 5. Measures for achievement of goals of programme for prevention of chronic bronchitis and 
COPD 
(1) Reduction in smoking 
(2) Reductions in work-related and outdoor air pollutants and improvement of quality of air 
indoors 
(3) Increase in knowledge about risk factors and treatment of the diseases in key groups 
(4) Promotion of early diagnosis and active treatment, among smokers in particular 
(5) Improvement of guided self-care 
(6) Early commencement of rehabilitation, planned individually and mainly implemented as an 
element in treatment 
(7) Encouragement of scientific research 
TABLE 6. Prevention of development of chronic bronchitis and COPD (primary prevention) 
Abstinence from smoking, avoidance of cigarette smoke during pregnancy and lactation in 
particular 
Smoke-free homes, day-care places, school and working environments 
Prevention of young people from starting smoking 
Encouragement of breast feeding and implementation of vaccination programmes 
Prevention of recurrent respiratory infections in children 
Balanced diet and adequate physical activity 
Prevention of exposure to harmful dusts in the working environment 
Improvement of quality of indoor air and air in communities 
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TABLE 7. Detection and control of chronic bronchitis and COPD at an early stage (secondary 
prevention) 
Cessation of smoking 
Avoidance of work involving risk of exposure 
Use of face-masks during short-term tasks involving exposure to dust 
Fitness exercise and preventive physical therapy 
Initial measures directed at risk groups 
Early diagnosis 
Good initial treatment and guidance 
Impravement of the quality of outdoor air and indoor air, at home and in places of work and public 
facilities 
Prevention strategies are aimed either at specific risk 
groups or the population in general. In the former case 
preventive methods are targeted at individuals at high 
risk of developing chronic bronchitis or COPD, such as 
smokers. The aim of the population-direct strategy is to 
reduce air pollutants, cigarette smoke in particular, both 
with respect to the entire population and the environment. 
RISK GROUPS AND INITIAL MEASURES 
TARGETED AT RISK GROUPS 
Initial measures targeted at risk groups allow early diag- 
nosis of the disease and implementation of measures to cure 
or alleviate it. In this context, pregnant women are also 
considered to constitute a risk group because their behav- 
iour affects the risk of the disease in the subsequent 
generation. Reduction of the risk of COPD helps reduce 
incidences of other diseases, such as cardiovascular dis- 
orders and cancer. Recent studies have shown that reduced 
lung function is a significant risk factor for coronary heart 
disease mortality, comparable to high blood cholesterol. 
Primary risk groups and corresponding initial measures 
are shown in Table 9. Important symptoms and findings 
and recommended initial measures are listed in Table 10. 
Examples of nicotine dependence test and mini-intervention 
are given in Appendices 2 and 3. 
TABLE 8. Prevention of exacerbation of COPD (tertiary 
prevention) 
Cessation of smoking 
Avoidance of dust and cigarette smoke in the environment 
Maintenance of good general condition, physical exercise 
training 
Correction of defective diets 
Pneumonia and influenza vaccinations 
Good treatment of respiratory infection 
Anti-inflammatory medication if necessary 
Justifiable symptomatic medication 
Protection against air-pollution peaks and cold weather 
Rehabilitation and use of respiratory care devices 
MEASURES DIRECTED AT INDIVIDUAL 
HEALTH BEHAVIOUR 
Prevention of smoking 
Primary measures directed towards prevention of smoking 
at population level supported by the health-care system are 
shown in Fig. 12. In Finland, the Act concerning measures 
directed towards reduction of smoking (Act 693/76) and its 
revision (Act 765/94) are demonstrations of a will to take 
measures to reduce the adverse health effects of smoking. 
The programme focuses on the most important tasks for 
the health-care system in relation to prevention of smoking, 
namely guidance and help with stopping smoking. 
Prevention of smoking should be an integral and con- 
tinuing element in the activities of all health-care staff. 
Smoking can be compared with other significant public- 
health risk factors. Various health-care units, such as 
child-welfare centres, school health-care and dental-care 
units, doctor’s surgeries and occupational health units 
should screen on a continual basis. When risk factors are 
observed, guidance and, if necessary, treatment should 
be provided. Response to treatment should always be 
monitored. 
Starting, often also stopping, smoking is a long-term 
process. The first phase consists of observation. A child 
makes observations relating to smoking and attitudes 
towards smoking in his or her environment. The second 
phase is one of experiment. During this phase, a young 
individual will usually smoke less than one cigarette a week. 
At this stage direct and indirect advertising of cigarettes 
encourages preservation of the habit resulting in social and 
psychological dependence. Experimentation with smoking 
can lead to habitual smoking, which is associated with the 
development of strong physical and mood-related depen- 
dence on nicotine. Pharmacological, social and psychologi- 
cal factors affect different individuals differently and 
withdrawal consequently needs to be planned individually. 
Basic methods of provision of guidance and information, 
and the nature of information given to children and young 
people, are summarized in Tables 11 and 12. 
Most smokers want to stop. Half will have considered 
stopping smoking, and will have attempted it seriously 
during the preceding 12 months. Most stop smoking by 
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TABLE 9. Primary risk groups for chronic bronchitis and COPD and recommended measures 
Risk group Measures 
Smokers Symptom questionnaire, nicotine dependence test, spirometry 
Pregnant women Smoking questionnaire, carbon monoxide measurement 
Children with unexplained Investigation of the environment, physical examination, 
chronic cough and production smoking questionnaire 
of mucus 
Young people trying smoking Smoking questionnaire, carbon monoxide measurement 
Individuals with recurrent Smoking questionnaire, carbon monoxide measurement 
respiratory infection 
Individuals with chronic cough Smoking questionnaire, spirometry, investigation of working 
at work environment and tasks, symptom diary 
Individuals exhibiting dyspnoea Symptom questionnaire, smoking questionnaire, ECG, 
below age 40 spirometry, oximetry, chest X-rays, physical examination, 
a,-antitrypsin determination 
TABLE 10. Significant abnormal symptoms, and findings and measures to be taken in relation to such 
symptoms and findings 
Finding Measures 
Smoking, experimenting with 
smoking 
Prolonged production of mucus 
Recurrent haemoptysis 
FEV, below 80% and/or MEF,, 
below 62% of reference value 
FEV, below 65% and/or MEF,, 
below 35% of reference value 
Problems in diagnosis or 
treatment 
Guidance, mini-intervention, planning for stopping smoking 
Physical examination 
Examination by a specialist in pulmonary diseases 
Physical examination 
Examination by a specialist in pulmonary diseases 
Examination by a specialist in pulmonary diseases 
themselves, without help. Some turn to close relations, 
smoking-withdrawal groups and, in particular, health-care 
staff. In 1996, only one smoker in four reported having been 
advised to stop smoking by a health professional. The 
figure has remained unchanged over the past decade 
(Fig. 13). 
The individual situations of patients trying to stop 
smoking need to be taken into account. Some patients will 
not yet have given serious thought to stopping smoking 
(preliminary phase), some will already have considered it 
seriously (preparatory phase), some will already be trying 
to stop, and some will already have stopped. Cessation 
of smoking in adults is described in Table 13. Possible 
solutions to common problems are listed in Table 14. 
Implementation of nicotine supplementation is described in 
Appendix 4. 
Prevention of infection 
Important research into vaccines and work on improve- 
ment of infection control have been conducted in Finland. 
In international terms, the population has taken a very 
positive stand towards vaccination. The preservation of this 
attitude is an important goal of health education. 
In children who suffer more than four to six episodes 
of respiratory infection a year, reasons for recurrence of 
infection should always be investigated, in addition to 
providing acute therapy. It is recommended that such 
children, and children with chronic bronchitis, be immu- 
nized against both influenza and pneumococcal infections. 
Patients suffering from moderate to severe COPD are at 
risk of influenza and should be given vaccinations every 
autumn. Vaccination reduces influenza morbidity and 
mortality by 70-80%. It can also help reduce the occurrence 
of sequelae of influenza, such as pneumonia. 
Vaccination against pneumococcal infections is recom- 
mended in patients with COPD because it provides protec- 
tion for several years, and reduces the risk of the 
pneumococcal infections becoming severe. 
Pulmonary chlamydial infections have been shown to be 
considerably more frequent in patients with COPD than in 
normal populations. However, causality is still unclear. In 
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FIG. 12. Reduction of adverse health effects of smoking. 
TABLE 11. Prevention of smoking in connection with small children and their parents 
Places of 
work 
Method Nature 
Ask and listen Smoking at home and in day-care centres 
Plans and experience in relation to stopping smoking 
Nicotine dependence test 
Discuss and encourage 
Recording of principal facts 
Positive effects of smoke-free air on child health 
Adverse health effects of cigarette smoke, as appropriate: 
Risk of miscarriage or premature delivery, 
Low birth-weight 
Recurrent respiratory infections, 
Chronic inflammation of the middle ear (otitis media) 
Stopping of smoking by parents and support required 
Follow-up visits relating to individuals trying to stop smoking 
Control and thank Situation in relation to smoking after pregnancy and breast-feeding 
Progression of stopping smoking and support required 
Non-smoking status, smoke-free home 
Success in stopping smoking 
future, prevention and treatment of chlamydial infections 
may prove useful in the treatment of COPD. 
mineral supplements are of no value unless patients exhibit 
marked deficiencies. Dietary recommendations supportive 
of the prevention and treatment of chronic bronchitis and 
Nutrition 
A balanced diet can help reduce risks and symptoms 
associated with chronic bronchitis and COPD. Vitamin and 
COPD are given in Appendix 5. 
Patients with severe COPD often suffer from prolonged 
undernutrition. In some COPD patients, respiratory func- 
tion may be impaired by obesity. Correction of nutritional 
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TABLE 12. Prevention of smoking in adolescents and stopping them experimenting with smoking 
Method Nature 
Ask and listen Experimentation with smoking and smoking habits of adolescents and their siblings and friends 
Successes and problems at school 
Experimentation with alcohol and drugs 
Attitudes of close relations towards smoking 
Plans and experience in relation to stopping smoking 
Nicotine dependence test 
Recording of principal facts 
Discuss and encouage Benefits of not smoking, and reduction of smoking in the population 
Skills required to be able to decline to smoke 
Control of social pressures and personal life 
Misleading points of view in cigarette advertisements 
Bad breath, gingival and dental problems, smelly clothes and hair 
Deterioration of dermal health and waste of money 
Attitudes and discussions about smoking at school and with friends 
Sports and other hobbies, decreased sporting performance 
Encouragement of stopping experimentation with smoking 
Stopping smoking, and referral to a withdrawal or social-support programme, if necessary 
Relp and support as wanted by the adolescent 
Follow-up visits for those experimenting with smoking or trying to stop 
Control and thank Smoking situation 
Progression of withdrawal and support required 
Non-smoking status, non-smoking friends, successful stopping of experimentation with 
smoking/smoking 
status forms an integral part of treatment. In addition to 
changing diet, it is important to find and implement suitable 
forms of physical exercise. 
Physical exercise 
Physical exercise has both direct and indirect effects. The 
physical and psychological effects of exercise improve self- 
esteem, general condition and the resistance of the organ- 
ism. A good general condition reduces susceptibility to 
respiratory infections and accelerates recuperation from 
such infections. Regular physical exercise helps prevent 
desire to smoke and increases mucus secretion and 
elimination of mucus from the airways. The effect of 
increased exercise on the lungs as such is less marked but 
it increases the strength and endurance of respiratory 
muscles, pulmonary ventilation, respiratory efficiency, 
and energy metabolism in muscles. Physical exercise 
also helps reduce the increased risk of bone loss in patients 
with COPD. It also increases opportunities for social 
contact. 
In addition to spontaneous physical activity and health- 
promoting exercise, physical exercise can be implemented in 
the form of guided training or as therapeutic physical 
exercise prescribed by a doctor. Guided training can even 
be organized in the context of public services relating to 
physical exercise. Recommendations in relation to the 
nature, extent and duration of physical exercise are given 
in Table 15. 
In planning physical exercise, each patient should be 
helped to find suitable and enjoyable forms of exercise. 
Increase in physical activity in adults is facilitated by the 
fact that children and young people are being instructed to 
adopt physical exercise as an integral part of their everyday 
lives both at school and at home. In providing guidance 
about increasing exercise, attention should be paid to an 
individual’s age, any diagnosis of cardiovascular disease, 
physical condition and previous physical activity. The 
possible impact of concomitant coronary heart disease on 
the safety of physical exercise (exertion level) should be 
assessed. Dyspnoea restricts levels of exertion in patients 
with severe COPD. Methods of reduction and improved 
management of exercise-induced dyspnoea are described 
in Table 16. 
Physical examination and clinical exercise testing before 
increasing physical activity are recommended for all indi- 
viduals with cardiac, pulmonary or metabolic disease, and 
for symptomless individuals over 40 years of age at high 
risk because of several risk factors. 
The environment 
Clean outdoor air furthers prevention and treatment of 
chronic bronchitis and COPD. New standard values for air 
quality, including odorous sulphur compounds, came into 
force in Finland on 1 September 1996. Impurities in out- 
door air may be involved in development of the disease, and 
aggravate symptoms. Communal-air pollutants can also be 
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TABLE 13. Phases and measures in relation to stopping smoking 
Phase Measure 
Preliminary phase Motivation 
Distribution of material 
Nicotine dependence test 
Explicit advice to stop smoking 
Arrangement of follow-up visit 
Preparatory phase Motivation 
Guidance in relation to means of stopping smoking 
Review of previous experience 
Distribution of self-care material, referral to a withdrawal group if necessary 
Recording of goals 
Agreement on day of stopping 
Arrangement of follow-up visit 
Stopping phase Support and guidance 
Management of difficulties and withdrawal symptoms 
Nicotine supplementation if necessary 
Arrangement of social support 
Arrangement of follow-up visit 
Staying non-smoker Thanking 
Support and guidance to aid preservation of permanent non-smoking status 
Management of risk situations 
Prevention of weight gain 
TABLE 14. Common problems in stopping smoking and suggested solutions 
Problem Solution 
Weight gain Avoidance of high-calorie foods 
Regular physical exercise 
Withdrawal symptoms Symptomatic treatment and guidance 
Relaxation, exercise and adequate hydration 
Nicotine supplementation 
Recommencement of smoking Analysis of problem situations and discovery of solutions 
Teaching of new models of behaviour 
Lack of social suppport Involvement of those in environment 
(e.g. family members) in withdrawal 
Behaviour therapy 
found indoors. Inorganic and organic dusts in air indoors 
can provoke symptoms in sensitive individuals. Smoking is 
the most important indoors problem and predisposes indi- 
viduals to harmful effects of outdoor air. The main prob- 
lems and suggestions for reduction of adverse effects are 
stated in Table 17. Most measures suggested also require 
official measures, revision of relevant rules and regulations, 
and international cooperation. In 1997, the Ministry of 
Social Affairs and Health published a report entitled 
Adverse Health Effects of Indoor Air and Suggestions for 
their Reduction. 
Diagnosis 
SYMPTOMS AND REASONS FOR SEEKING 
MEDICAL ATTENTION 
The first symptom of chronic bronchitis is cough and pro- 
duction of mucus in the morning. Symptoms often become 
worse during episodes of the common cold in winter, result- 
ing in purulent sputum, possibly dyspnoea and wheezing 
and, occasionally, elevation of body temperature. Common 
colds readily progress to bronchitis and pneumonia. 
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FIG. 13. Opinions of smoking men about smoking, their 
attempts at stopping smoking, and advice to stop 
smoking given by the health-care personnel in 1978 to 
1996 (---, wants to stop smoking; ---: has been 
advised to stop smoking by health-care personnel; 
., has tried to stop during the preceding 6 months; 
-. -, concerned about the hazardous effects of 
smoking on personal health). Reproduced with permission 
from National Public Health Institute (1996). 
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In children, symptoms of chronic bronchitis include 
unexplained cough, wheezing on expiration, production of 
mucus and decreased bronchoconstriction threshold. Since 
children often swallow their sputum, mucus hypersecretion 
and the increased amounts of sputum detectable in adults 
often remain unobserved. If chronic bronchitis is suspected, 
the child must be referred to a specialist. 
As the disease progresses, exacerbations become increas- 
ingly frequent and healthy periods between exacerbations 
become shorter. Cough and production of mucus occur 
throughout the 24 h of a day. Dyspnoea, associated with 
narrowing of the airways and/or worsening of emphysema, 
is primarily exertional dyspnoea. Patients become accus- 
tomed to the symptom and do not appreciate it until it 
imposes severe limitation on work and other activities. In 
severe COPD, dyspnoea can occur even during dressing, 
bending or working with the hands. 
Patients are often fearful and depressed because of their 
symptoms. Undernutrition and weight loss is common. 
Hypoxaemia in the brain resulting from impaired oxygen 
uptake causes irritation, depression, memory impairment 
and difficulties in concentrating. Accumulation of carbon 
TABLE 15. Recommendations in relation to physical exercise for patients with chronic bronchitis and 
COPD 
Chronic bronchitis and mild to moderate CBPD 
Practice of correct breathing technique 
Exercise increasing endurance 
About 30 min until the patient gets out of breath, preferably daily 
Daily exercise can be implemented in two to three phases 
Suitable forms of exercise: walking,. skiing, cycling, swimming, dancing 
Exercise improving muscle fitness 
Severe COPD 
Daily exercise at an appropriate level of exertion 
Exercise helping to maintain muscle strength 
Short exercises involving eight to 10 contractions of different groups of muscles 
Exercise of the respiratory muscles and accessory respiratory muscles 
Strengthening of the abdominal muscles to improve expiration and coughing 
Strengthening of the upper and lower back muscles to improve posture 
Strengthening and stretching of the neck and shoulder muscles 
Strengthening of the muscles of the upper and lower extremities to improve coping with daily 
activities and hobbies 
Exercise to improve movement of the thorax 
Patients with COPD should only participate in physical exercise that can be safely interrupted at any 
time 
TABLE 16. How to reduce and control exercise-induced dyspnoea in patients with COPD 
Ensure adequate stretching and warming-up, and gradual increase of exertion 
Good treatment of the disease, medication before exercise 
Learning an economic method of breathing, pursed-lips breathing 
Sufficient intake of fluids, keeping warm 
Taking exercise periodically and changing levels of exertion 
Protection of the face and warming of inspired air in cold weather 
Gradual decrease in levels of exertion during each exercise, and stretching at the end 
Taking physical exercise with friends 
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TABLE 17. Problems caused by airborne impurities in the environment and measures for reduction of 
their adverse effects 
Problems Measures 
Smoking indooors 
Work-related exposure 
Smoke-free home 
Enforcement of provisions of the Tobacco Act in 
public facilities and workplaces 
Non-smoking sections in restaurants 
Health education, information and guidance 
Improvement of methods of work and cleanliness of 
the working environment 
Technical and hygiene-related solutions to reduce 
exposure 
Emissions from traffic and microparticles Reduction of emissions from individual cars 
Promotion of walking, cycling and rail transport 
Information, advice and restrictions 
Extreme cold and smog Improvement of information about air pollutants 
Avoidance of exposure to outdoor air during extreme 
cold and peak pollutant levels 
dioxide as a result of decreased pulmonary ventilation can 
cause morning headache. Peripheral oedema associated 
with undernutrition or impaired cardiac function may also 
occur. 
At an early stage, when intervention can still have a 
significant effect on the course of the disease, patients often 
present for examination and treatment for reasons other 
than the symptoms commonly associated with chronic 
bronchitis or COPD. When patients seek medical attention 
because of symptoms clearly associated with COPD, over 
20 years will usually have elapsed since onset of the disease. 
The commonest reasons for which patients seek medical 
attention are listed in Table 18. 
DIAGNOSIS AND EXAMINATION 
Pvimavy and occupational health-cave services 
Diagnosis of chronic bronchitis without narrowing of the 
airways is based on a history of risk factors and symptoms. 
A thorough interview should be carried out to investigate 
exposure factors at home and in the working environment, 
exacerbation of symptoms in the winter and during infec- 
tions, and the durations and frequency of such exacer- 
bations. A general examination should be conducted to 
exclude other illnesses. Pulmonary auscultation findings 
and results of lung function tests are usually normal. 
Determination of inflammatory factors in sputum may 
soon provide a key to improved early diagnosis. 
Progression of the disease from chronic bronchitis to 
COPD can be detected at an early stage only with the help 
of lung function tests. Spirometry is the most important aid 
to diagnosis and determination of severity of disease. The 
examination requires experience on the part of the clinician, 
and active collaboration of the patient is important if 
TABLE 18. Reasons for seeking treatment in chronic 
bronchitis and COPD 
Chronic bronchitis and mild CODP 
No pulmonary symptoms, patient seeks medical attention 
for other reasons 
Cough and production of mucus in the morning 
Repeated respiratory infection 
Prolonged cough 
Haemoptysis 
Moderate to severe COPD 
Dyspnoea on mild to moderate exertion 
Cough and hypersecretion of mucus and episodes of 
bronchitis 
reliable results are to be obtained. Measurements must be 
well standardized. A new recommendation relating to con- 
duct of spirometry and assessment of results was issued in 
1997. Forced expiratory volume in 1 s (FEV,) is decreased 
in bronchial obstruction but can also be diminished in other 
pulmonary diseases. Obstruction of the small airways 
developing at an early stage in COPD can be detected with 
the help of a flow-volume spirometer. A rapid decrease of 
forced vital capacity (FVC) with FEV, can be a result of 
air trapping in the small airways. FEV,/FVC below the 
reference value confirms airways obstruction. 
In moderate COPD, decreased arterial partial pressure of 
oxygen can occur. Oxygenation of arterial blood and tissues 
decreases as the disease progresses. High haemoglobin and 
haematocrit values can be signs of chronic hypoxia, for 
example, during the night. Impaired oxygen intake is 
manifest in a bluish discoloration (cyanosis) of the skin and 
mucosa when arterial oxygen saturation (SAO& is below 
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80%. Oxygen saturation can be measured with the help of, 
e.g., a pulse oximeter, using a finger or ear transducer. If the 
device is equipped with memory it can be used for long- 
term monitoring of oxygenation, for example during the 
night. 
In severe COPD, pronounced airways obstruction and 
emphysema result in air trapping and increased inflation of 
the lungs and aggravation of hypoxia in arterial blood and 
tissues. Respiratory sounds diminish, heart tones are dis- 
tant, expiration is prolonged and diaphragmatic motion 
is decreased. In the most severe cases, a barrel-chested 
appearance develops. Marked use of accessory respiratory 
muscles or pursed-lips breathing may be seen. In some 
patients, increased resistance of the pulmonary circulation 
results in development of failure of the right side of the 
heart, leading to increased pressure in the superior and 
inferior vena cava, hepatic enlargement and peripheral 
oedema. Changes observed in chest X-rays may include 
depression and tenting of the diaphragm, increased retro- 
sternal air space, pronounced hilar vessels and attenuation 
of peripheral vascular markings. However, a normal X-ray 
does not exclude COPD or emphysema. 
In differential diagnosis, asthma, pulmonary fibrosis, 
lung cancer, tuberculosis and many other disorders of lung 
tissue should be taken into account. Tests used to exclude 
asthma include spirometry, monitoring of peak expiratory 
flow (PEF) at home and in the working place to determine 
reversibility of and fluctuation in airways obstruction, and 
trial of steroid therapy. In COPD, PEF is decreased only in 
advanced cases and the decrease is usually irreversible. 
Eosinophilia suggests asthma, but asthma and COPD can 
coexist. 
An association of chronic bronchitis with work should be 
considered if a patient suffers from persistent dry cough, or 
cough with production of mucus that has started during 
employment involving exposure to risk factors. The symp- 
toms have a quantitative relationship to periods of work, 
and on the basis of examinations they are not associated 
with common lung and respiratory diseases. Atopy appears 
to increase occurrence of symptoms. Smoking complicates 
assessment of causal relationships. 
Course of the disease is monitored with the help of 
repeated FEV, measurements. A decrease in FEV, 
(normally about 28 ml year ~ ‘) exceeding 50 ml year ~ ’ 
indicates rapid progress of the disease. Response to 
medication is monitored with the help of bronchodilation 
test, PEF measurements and trials of oral corticosteroid 
therapy (more in Drug therapy below). Several question- 
naires have been prepared for monitoring quality of life but 
at present, use of such questionnaires is limited primarily to 
scientific studies. 
During exacerbation, wheezing sounds or rhonchi may 
be audible during forced expiration, and expiration may 
be prolonged. Haematological tests provide indications 
of possible aetiological factors. Sputum culture is often 
unnecessary. Chest X-rays are important to exclude 
pneumonia and pneumothorax. In severe COPD, severity 
of exacerbation can be estimated roughly on the basis of 
respiratory frequency, pulse rate, use of accessory respirat- 
ory muscles, cyanosis, dysfunction of respiratory muscles 
TABLE 19. Examinations in primary health care and 
occupational health care 
asic examinations 
History-taking, charting of risk factors 
Auscultation of the lungs, including forced expiration 
Examinaiion of paranasal sinuses and the adenoid 
Chest X-ray, ECG 
Bacteriological and cytological sputum tests, if considered 
appropriate 
Flow-volume spirometry and bronchial dilation test 
Monitoring of diurnal fluctuations in PEF values 
Follow-up examinations 
Clinical examination 
Spirometry 
Examinations during exacerbation 
History-taking, clinical examination 
Haematological tests for infection 
Chest X-ray, ECG 
Pulse oximetry 
(uncoordinated movement of the thorax or paradoxical 
abdominal movement and retraction of lower intercostal 
spaces): and tiredness. 
The tasks of primary care and occupational health 
services in relation to diagnosis of chronic bronchitis and 
COPD include early diagnosis, identification of moderate 
and severe COPD and referral of patients to specialized 
medical care for assessment, and intensive monitoring of 
patients. Examinations to be conducted in primary health 
care and occupational health care are shown in Table 19. 
Specialized medical care 
In specialized medical care, latent COPD in smokers should 
be taken into account in connection with all contacts with 
patients, irrespective of the speciality. Apart from this; the 
main tasks in the area of pulmonary disease include diag- 
nosis of moderate to severe COPD, and investigation of the 
degree of emphysema associated with the disease, the 
prognosis of the disease, and the presence of any coexisting 
disease significantly affecting treatment. 
Inflammation of the bronchial mucosa is not visible on 
chest X-rays and cannot be detected via routine blood tests. 
Bronchoscopy provides direct information about the con- 
dition of the mucosa. Bronchoscopic examinations are 
limited primarily to diagnostic problems, investigation of 
bronchitis in children and adolescents, and cases in which 
work-related disease is suspected. 
The severity of emphysema can be assessed by means 
of measurement of diffusing capacity. Although the 
examination is not specific to emphysema, it often helps 
in distinguishing patients with emphysema from, e.g., 
asthmatic patients, who do not usually exhibit low diffus- 
ing capacities. The examination can be conducted in a 
clinical physiology laboratory, or in a laboratory of a unit 
specializing in pulmonary disease. 
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In patients with COPD, the arterial partial pressure of 
oxygen (PAOJ decreases because of uneven distribution of 
pulmonary ventilation. A low diffusing capacity usually 
reduces PAO, only on exertion. PAO, reflects the oxygena- 
tion of the entire organism and is affected by many factors 
other than COPD and emphysema, such as diffuse pulmon- 
ary diseases causing fibrosis, and shunts. Monitoring of 
arterial blood gases for impairment of gas exchange is 
necessary. A decrease in PAO, to below 8.0 kPa and an 
increase in the arterial partial pressure of carbon dioxide 
(PACO,) to more than 6.5 kPa are signs of respiratory 
insufficiency. 
Exercise testing can be used to determine basic physical 
condition before physical exercise is started, to determine 
the pulse level to be used for improvement of physical 
condition, and to allow capacity for work and any coexist- 
ing diseases, such as coronary heart disease, to be evalu- 
ated. Assessment of tolerance of exercise is particularly 
important if dyspnoea appears to be excessive in relation to 
FEVi. 
Deficiency of a,-antitrypsin should be suspected if a 
young patient has developed emphysema following 
relatively minor smoking. 
Measurement of respiratory muscle strength is recom- 
mended if a patient’s nutritional status is poor, if steroid- 
induced muscle weakness is suspected, or if dyspnoea or 
PACO, increase is excessive in relation to changes in FEV,. 
It should also be borne in mind that PAO, decreases 
during sleep. Thorough oximetric determinations during 
sleep are necessary if pulmonary heart disease or increased 
red cell mass occurs in association with mild airways 
obstruction and if concomitant sleep apnoea is suspected. 
Severe COPD is often associated with increased resist- 
ance of the pulmonary circulation, and with pulmonary 
heart disease, the severity of which affects the prognosis. 
Pulmonary arterial pressure can be measured by means of 
echocardiographical examination and catheterization of the 
right side of the heart. However, these examinations are not 
undertaken routinely because the overall prognosis can be 
fairly readily assessed via lung function tests, blood gas 
analyses, chest X-rays and ECGs. 
Recommendations regarding examinations to be con- 
ducted in connection with specialized medical care are given 
in Table 20. 
Improvement of treatment 
GOALS AND MEANS OF TREATMENT 
If treatment is to be successful, and the disease is to be 
cured, it is important that patients with chronic bronchitis 
or COPD know and understand the causes of the disease 
and the possibilities for and results of treatment. It is also 
important for patients to trust themselves, and the treat- 
ment organization. Goals of treatment in patients with 
chronic bronchitis and COPD are shown in Table 21. 
Means of achieving these goals are listed in Fig. 14. 
Treatment should depend on the cause of the disease, and 
should be focused on factors causing or aggravating the 
disease. 
TABLE 20. Examination of COPD patients under specialized 
medical care 
Basic examinations 
History-taking and status 
Chest X-ray (if necessary) 
Flow-volume spirometry and bronchodilator response (if 
necessary) 
Monitoring of diurnal fluctuations of PEF values (if 
necessary) 
Blood count (if necessary) 
Diffusing capacity 
Arterial blood gas analysis 
Exercise test 
In children, immunoglobulin levels (IgA in particular) 
Tests in special cases 
a,-antitrypsin 
Volume spirometry, body plethysmography 
Spiroergometry 
Computerized tomography (HRCT) 
Bronchoscopy 
Measurement of respiratory muscle strength 
Assessment of respiratory disturbances during sleep 
Measurement of pulmonary arterial pressure 
TABLE 21. Goals of treatment in patients with chronic 
bronchitis and COPD 
5. 
6. 
Recovery of patients with chronic bronchitis 
Maintenance of capacity for work and functional 
ability at as high levels as possible 
Decrease in frequency or severity of symptoms of the 
disease, and of exacerbations 
Cessation of or decline in rate of deterioration of 
pulmonary function 
Reduction in complications of the disease or 
alleviation of symptoms caused by such complications 
Improvement of quality of life 
Early rehabilitation improves the facility of individuals to 
make appropriate use of existing resources. In severe 
COPD, patients should be instructed to employ their dimin- 
ished physical resources appropriately, and in economic 
ways. 
Drug therapy is important in alleviating symptoms and 
improving quality of life. Respiratory care devices can be 
used, if necessary, to enhance drug therapy. Hospital treat- 
ment is necessary during severe exacerbations and surgical 
treatment. In addition, a prescheduled period of hospital- 
ization can be used to intensify overall treatment and to 
give patients and their families an opportunity to rebuild 
resources. Commencement of rehabilitation at an early 
stage should form an element in treatment overall. 
There is no reliable evidence that alternative therapies are 
of significance in chronic bronchitis and COPD. 
Stopping smoking, measures directed towards the 
working environment, vaccination and nutrition have been 
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Treatment of chronic bronchitis and 
chronic obstructive pulmonary disease 
Treatment according 
to cause I I 
Early rehabilitation 
I I 
H Vaccinations 
I ’ I 
I I , 
4 Correction of nutritional defects 
Drug therapy 
of exacerbations 
1 H H~~~~~~et~~~~~~~t / 1 / Professional 
~l--GiLq~,,., 
care devices 
1 Oxygen therapy 
FIG. 14. Methods of treatment of chronic bronchitis and COPD. 
discussed above. The following sections focus on early 
rehabilitation, drug therapy, hospital treatment and 
rehabilitation in general. 
HIERARCHY OF REFERRALS FOR TREATMENT 
Chronic bronchitis and COPD are prevented and treated 
via regional collaboration between personnel working in 
primary health care, specialized medical care and other 
bodies. Primary responsibility for prevention and treatment 
is borne by the primary care system, flexibly supported by 
the specialized medical care sector. The specialized medical 
care sector is primarily responsible for regional planning, 
training of instructors, and quality control in relation to 
measures for prevention and treatment. Hospital districts 
and health centres should ensure that the various levels 
of the health-care system are capable of appropriate 
performance of tasks assigned to them. 
It is recommended that each hospital district appoints a 
specialist to be in charge of prevention and treatment of 
chronic bronchitis and COPD. The individual concerned 
should be responsible for establishment and maintenance of 
regional know-how, and the quality of prevention and 
treatment. In primary care, local contacts should be 
appointed to distribute information, coordinate training 
and promote collaboration with, e.g., dental personnel. 
Regional individuals in charge are responsible for the 
organization of regional training and consultation within 
the specialized medical care sector, and should monitor the 
success of prevention and treatment in their region with 
local contacts. Such a system has already been created in 
connection with the National Asthma Programme, and it 
would be most appropriate that the individuals in charge 
and acting as contacts were also responsible for issues 
concerning asthma. 
The primary health-care system is responsible for treating 
patients, unless their treatment has temporarily been trans- 
ferred to the specialized medical care sector (Fig. 15). The 
starting point is for the attending physician to arrive at a 
diagnosis, and start appropriate treatment and follow-up. 
Successful scaling of treatment requires good collaboration, 
rapid and flexible admission of patients and good flows of 
information between different levels of health care. These 
activities should be supported by appropriate service and 
treatment chains. 
TREATMENT 
Early rehabilitation and guided self-cave 
The aim of early rehabilitation is to maintain the capacity 
of individuals for work and their functional abilities or to 
prevent them from diminishing. Activities to maintain 
capacity for work have already been organized within the 
occupational health care sector. They include preventive 
activities for healthy employees. Early rehabilitation should 
be increased in other health-care sectors. As far as forms of 
early rehabilitation in relation to treatment of individual 
patients are concerned, physical exercise training has been 
discussed above. In this section, patient education and 
preventive physical therapy are discussed. Appropriate 
guided self-care, with the patient assuming responsibility 
for his or her health at an early stage, can help towards 
optimization of treatment results. 
Patient education and guided self-care 
Chronic illness always involves a period of adaptation. 
Defence and adaptation strategies vary between individ- 
uals, and can manifest themselves in different ways. A 
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Education, vaccinations, and activities 
aimed at influencing environmental measures 
Measures directed towards risk groups 
I Diagnosis, treatment and follow-up of chronic bronchitis I 
Diagnosis, treatment and follow-up of 
mild to moderate COPD 
I Treatment and follow-up of severe COPD as agreed I 
I Patient education and guidance I 
Follow-up of use of respiratory care 
devices as agreed 
I Instruction and patient education I 
t 
Direction of measures directed 
at risk groups I 
I Examination and treatment in relation to chronic bronchitis in children 
Examinations relating to cases of 
bronchitis suspected to be work-related 
Assessment, treatment instructions and 
prognosis in relation to moderate COPD 
I Diagnosis, treatment and surgical treatment of severe COPD 
Problems in diagnosis, 
and assessment of capacity for work 
I Initiation and follow-up of use of respiratory care devices, and training of instructors 
I Hospital treatment of severe exacerbations 
Improvement of diagnosis, follow-up 
and quality control of treatments 
FIG. 15. Division of work between primary health care and specialized medical care systems in the prevention and 
treatment of chronic bronchitis and COPD. 
patient may deny the existence of a disease and its impact 
on his or her life, completely or partially, or may exaggerate 
problems. 
Patient education is fairly time-consuming. It should 
focus primarily on helping patients analyse their life situa- 
tions, manage disease and cope with changes caused by 
disease. Patients, relatives and their work communities 
should be advised to provide support for patients. Success- 
ful patient education is based on good communication 
between patients and educators. The success of education 
can be verified immediately on the basis of personal feed- 
back from patients, subsequently by monitoring how 
patients implement instructions and advice given in their 
daily lives. However, education alone will not produce 
results or change patient behaviour. It needs to be 
accompanied by practice. 
In guided self-care, patients are given basic information 
about chronic bronchitis and COPD. The phases and 
prognosis of the disease, its effects on family and working 
life, and means of reducing risks of exacerbation are 
explained to the patient. Guidance should be given in 
accordance with the severity of each patient’s condition. 
The nature and effects of treatment, the purposes and 
side-effects of drug therapy, and the fundamental nature of 
guided self-care should be explained to patients (Table 22). 
Crisis plans for exacerbations should be prepared 
TABLE 22. Basic elements of guided self-care 
Stopping smoking 
Independent exercise to improve physical condition and 
muscle strength 
Crisis plans 
Appropriate vaccinations 
Ensuring correct nutrition 
Control of long-term medication 
FINNISH GUIDELINES FOR CHRONIC BRONCHITIS AXD COPD 317 
TABLE 23. Prerequisites for successful guided self-care 
A flexible treatment organization responsible for direction 
and follow-up of care 
Individual, thorough and repeated education 
Clear self-care material (instructions concerning stopping 
smoking, instructions regarding action in different 
situations, teaching material relating to COPD) 
A patient who is active in taking care of his or her 
personal welfare 
individually, taking account of each patient’s social 
environment. It is important to predict aggravation of 
situations. Rescue medication kept at home, such as anti- 
biotics and corticosteroid tablets, can help prevent aggra- 
vation of a situation at an appropriate time. It is important 
to reserve adequate time for discussion with a doctor or 
nurse. 
During follow-up a patient’s subjective condition should 
be examined, and progression of treatment checked as well 
as the development in physical and social activities, 
medication (doses, technique) and treatment instructions. 
Guidance should be repeated in relation to areas in which 
progress has been poor: necessary prescriptions (including 
prescriptions for rescue medication) issued to the patient, 
and the goals and a date for the next appointment fixed. 
Successful self-care requires individual patient care and a 
good patient-provider relationship and treatment organiz- 
ation (Table 23). In children, self-care will be successful 
only if the whole family participates. Patients should never 
be left to their own devices. Rapid access to assessment by 
a nurse: or a doctor if necessary, should be ensured at all 
times. 
Preventive physiotherapy 
The goals of physiotherapy are shown in Table 24, 
measures required for achievement of these goals in 
Table 25. Implementation of physical therapy requires 
participation by and responsibility on the part of the 
patient. 
In mild to moderate COPD, the primary task in physio- 
therapy is to instruct and motivate patients to take physical 
exercise and to use correct breathing techniques, at rest and 
during exercise, Changing from ‘chest out-stomach in’ 
type of breathing to a technique involving correct use of the 
diaphragm and intercostal muscles is a long-term process 
requiring independent daily practice by the patient. Muscle 
exercises can help increase the strength of the diaphragm 
and accessory respiratory muscles. 
In severe COPD, patients need to know what they are 
capable of; but also what their limitations are. The aim is to 
find solutions to problems encountered in coping with daily 
tasks at home. The patient should learn to control breath- 
ing even under difficult conditions such as exertion or 
exacerbation of the disease. Relaxation and breathing tech- 
niques and pursed-lip breathing can be used to improve 
lung function and reduce airways resistance. Unfavourable 
TABLB 24. Goals of physiotherapy in the treatment of 
chronic bronchitis and COPD 
1. 
2. 
3. 
4. 
5. 
For the patient to be physically active and aware of 
the possibilities allowed and limitations imposed by 
the disease 
For the patient to master the correct breathing 
techniques at rest, during physical activity and during 
attacks of dyspnoea 
For the patient to know how to remove secretions 
from the lungs 
For the patient to know how to prevent or correct 
incorrect posture and to maintain or improve 
movement of the thorax 
For the patient to be familiar with at least one 
relaxation technique 
TABLE 25. Physiotherapy measures in the treatment of 
chronic bronchitis and COPD 
1. Maintenance and improvement of physical condition 
Discovery of a suitable form of physical exercise 
2. Breathing pattern 
Correct breathing pattern, breathing training 
Positions promoting relaxation and facilitating 
breathing 
3. Prevention of incorrect posture 
Muscular relaxation 
Exercises to increase movement of the thorax 
4. Removal of lung secretions 
Physical activity 
Deep breathing movement combined with correct 
coughing technique 
Abdominal muscle exercises 
Breathing against counterpressure 
Inhalation therapy 
5. Relaxation exercises 
6. Charting of respiratory care devices 
positioning of the diaphragm can be corrected by, e.g. 
leaning forwards, and by pursed-lip breathing. Needs for 
respiratory care devices should be investigated and their 
correct use checked. The patient should be given moral 
support and encouraged to take independent action. 
Drug therapy 
The aim of drug therapy is elimination of symptoms and 
improvement in quality of life. In COPD, medication rarely 
results in normalization of lung function because airway 
obstruction is only partially reversible. In severe COPD, in 
particular, changes in symptoms and quality of life are 
more important for assessment of response to treatment 
than results of hung-function tests. Table 26 shows the 
indications for the most important drugs used to treat 
chronic bronchitis and COPD. The strategy for drug 
therapy is described in Fig. 16. 
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TABLE 26. Drugs used in the treatment of chronic bronchitis and COPD, and their purposes 
Drug Purpose 
Bronchodilators Smooth muscle relaxation in airways 
/& agonists Improvement of ciliary function 
Anticholinergic agents Reduction of effects of exertion and cold weather 
Theophylline Increasing the strength of the diaphragm 
Anti-inflammatory drugs Prevention and correction of mucosal damage 
Inhaled corticosteroids 
Oral corticosteroids 
Antibiotics 
Oxygen 
Treatment of bacterial infection 
Compensation of temporarily or permanently impaired oxygen intake 
Improvement of impaired functional ability 
Reduction of elevated pulmonary artery pressure 
Reduction in increased red cell mass 
Smoking 
withdrawal 
corticosteroid 
for 3 to 6 months 
Smoking 
withdrawal 
anticholinergic or 
sympathomimetic 
If y;~ay~=$Yz 
l---l 
corticosteroid 
for 3 to 6 months 
at discretion 
I Smoking withdrawal 
Theophylline 
if necessary 
If ;;Fas;yY> 
corticosteroid 
for 3 to 6 months 
at discretion 
Smoking 
withdrawal 
Inhaled 
anticholinergic or El sympathomimetic agent 
Long-acting 
theophylline 
corticosteroid or 
corticosteroid tablets, 
Medical oxygen 
if necessary 
FIG. 16. Drug therapy of chronic bronchitis and COPD. 
Inhaled drugs are central to drug therapy. However, in 
patients with COPD such drugs are often poorly distributed 
to the minute branches of peripheral airways. Before start- 
ing, and changing or increasing drug therapy it is necessary 
to be sure that the drug will be delivered to areas important 
in relation to treatment. Conditions for the effective use of 
inhaled drugs are shown in Table 27. In treatment of 
chronic bronchitis in children, the whole family should be 
instructed in use of the medicines. 
Response to bronchodilator therapy should be tested 
with the help of spirometry and PEF measurements 
at home. In most patients with COPD, testing of 
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TABLE 27. Factors reducing the effects of inhaled drugs in 
COPD, and measures directed towards the elimination of 
such factors 
Problem Solution 
Smoking Smoking withdrawal 
Mucus obstructing the Physical exercise 
bronchi Physiotherapy 
Antibiotics if necessary 
Poor inhalation technique Checking of technique and 
guidance 
Use of inhalation devices 
Weak respiratory muscles Physiotherapy 
Independent regular muscle 
exercises 
Poor patient compliance Patient education 
Charting of mental state and 
social situation 
bronchodilation shows improved FEV, values, Lack of 
response in a single test should never be a reason for 
discontinuation of treatment. 
/J’~ agonists (e.g. salbutamol) have a direct effect on 
bronchial smooth muscle, and dilate the bronchi. When 
symptoms of dyspnoea occur only on exertion or in cold 
weather, short-term & agonists rapidly alleviate or prevent 
symptoms. Long-term /$ agonists can be useful in reducing 
morning symptoms, in particular. pZ agonists also improve 
ciliary function and consequently bronchial clearance. The 
efficacy of medication increases with dose. However, side- 
effects such as muscle tremor, cardiac symptoms and 
arrhythmias prevent use of high doses. Oral /& agonists 
should be avoided. 
Anticholinergic agents (e.g. ipratropium bromide) dilate 
the bronchi and reduce secretion of mucus. They may also 
protect the bronchi against the reflex constriction caused by 
cold weather. Medication should be taken regularly, three 
to four times a day. In patients exhibiting symptoms daily, 
anticholinergic agents can be more effective than /& agon- 
ists. They have practically no side-effects. On exacerbation 
of symptoms, efficacy of treatment can be increased by 
combining an anticholinergic agent with a pZ agonist. 
Theophylline dilates the bronchi, reduces non-specific 
sensitivity of the bronchi, stimulates breathing and facili- 
tates removal of mucus from the bronchi. In long-term use 
it may increase the strength of the diaphragm in patients 
with COPD. Theophylline also enhances cardiac function, 
Exercise tolerance may improve without improvement in 
the results of lung function tests. The tablet formulation is 
easy to administer and is recommended especially when 
delivery of inhaled drugs is poor because of anatomical 
factors or a patient’s poor ability to inhale a drug. A 
long-acting form taken at night reduces early morning 
symptoms. A suitable dose can be determined by measuring 
the blood theophylline concentration. If theophylline is 
of no help, medication should be discontinued to avoid 
side-effects such as stomach problems and headache. 
The status of anti-inflammatory drugs in the treatment of 
chronic bronchitis and COPD remains controversial, and is 
the subject of extensive study. During and after exacer- 
bations prolonged inflammation of the bronchi that can 
persist for months and may be associated with hyper- 
reactivity is often observed. In some patients inhaled corti- 
costeroid therapy (for 336 months) helps alleviate the 
inflammation. Treatment is more effective in the early 
stages of the disease, when airways obstruction is mild. 
Even in severe COPD, lo-20% of patients react favourably 
to oral corticosteroid therapy, and one in four of these 
patients are believed to benefit from inhaled corticosteroids. 
Response to treatment should be assessed by means of 
spirometry and treatment should be continued only in 
patients with objective response. Patients should also be 
informed that inhaled steroids do not protect against the 
adverse effects of cigarette smoke. In some patients, benefit 
from the medication may be linked with the asthmatic 
component associated with the disease. Inhaled corticoster- 
oids have proved safe to use. Local side-effects (thrush and 
hoarseness) can be reduced by stopping smoking, rinsing 
the mouth and pharynx after taking the medicine, and using 
a spacer. 
In patients with severe COPD, the value of continuous 
corticosteroid therapy should be assessed by trying oral 
corticosteroid therapy (3040 mg of prednisolone day - ‘) 
for 2-3 weeks. If results of lung function tests improve (over 
10% increase in FEV, and an absolute increase of at least 
200 ml) the patient may benefit from regular therapy with 
an inhaled corticosteroid. A very good response (FEV, 
increases of over 20%) suggests asthma rather than COPD 
alone. If long-term regular systemic steroid therapy is 
necessary in exceptional cases, dosage should be low 
(5-10 mg of prednisolone day- ‘). 
New drugs affecting pathogenesis and disease develop- 
ment are being developed for the treatment of chronic 
bronchitis and COPD. These drugs will probably result in 
better means of treatment of these diseases. 
The role of mucolytic agents in treatment is controver- 
sial. A new-generation mucolytic appears promising. Its 
status in treatment seems likely to be established in the near 
future. Cough suppressants should be used with care. 
Oufpafienf fveafmenf of exacevbafions 
In treating exacerbations of symptoms, reasons for them 
should be investigated (Table 28). In elderly patients with 
severe COPD, in particular, acute episodes of co-existing 
disease often result in sudden aggravation of pulmonary 
symptoms. 
In COPD, symptoms often subside rapidly on addition of 
bronchodilator medication administered using nebulizers. 
Corticosteroid and theophylline therapies are also useful. In 
patients with severe COPD oxygenation may be tempor- 
arily impaired. Administration of oxygen via nasal cannu- 
lae at a rate of one to two 1 per min usually provides relief, 
often without significant accumulation of carbon dioxide. 
Exacerbations are often caused by a virus; but viral 
infection can also lead to spread of colonized bacteria to 
the lower airways, resulting in active bacterial infection. 
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TABLE 28. Differential diagnosis of exacerbations of chronic 
bronchitis and COPD 
Viral or bacterial infection 
Pulmonary embolism 
Myocardial infarction 
Aggravation of heart failure 
Spontaneous pneumothorax 
Medication (hypnotics and other drugs with CNS effects, 
beta blockers) 
Metabolic disorders (e.g. diabetes, electrolyte 
disturbances) 
Muut sairaudet (esim. refluksitauti, suolistovuoto) 
Incorrect oxygen therapy 
TABLE 29. Medical devices for medication and respiratory 
support of COPD patients 
Devices used in inhalation therapy 
Metered-dose inhalers and spacers 
Dry powder inhalers 
Nebulizers 
Jet nebulizers 
Ultrasonic nebulizers 
Intermittent positive pressure therapies 
Jet nebulizing (or oxygen) and intermittent positive 
pressure breathing 
Nasal intermittent positive pressure ventilation 
(NIPPV) 
Oxygen delivery systems 
Oxygen concentrators 
Gaseous oxygen in high-pressure cylinders 
Liquid oxygen systems 
Bacterial infection is most frequently caused by Strepto- 
coccus pneumoniae, Haemophilus injluenzae and Movaxella 
catavrhalis. A course of wide-spectrum antibiotic (lo-20 
days) can be started without bacterial culture and is usually 
sufficient. 
Respiratory caYe devices 
There are several kinds of medical devices that support 
drug therapy and breathing of COPD patients (Table 29). 
In Finland approximately 2000 patients administer drugs 
with regular nebulizers or positive pressure devices and over 
1000 patients are using domiciliary oxygen therapy. 
The routine therapy of choice is inhalation therapy, 
either with a metered-dose inhaler combined with a spacer 
or a dry powder inhaler. If peak expiratory flow (PEF) 
values of COPD patients are permanently below 
200 1 min ~ ’ or the inspiratory flow is low, the effective use 
of inhalation therapy may be difficult. Problems in using 
inhaler therapy may also be caused by difficulties in 
co-ordinating breathing or changes in finger joints. In such 
cases it may be necessary to use compressor-driven 
TABLE 30. Indications for use of nebulizers and intermittent 
positive pressure devices 
Low respiratory volume and high respiratory frequency 
Substantial inspiratory effort, intensive use of accessory 
respiratory muscles 
Poor alveolar ventilation (carbon dioxide retention) 
Excessive viscous mucus in the airways 
The patient needs inhaled medication, but is unable to 
use an inhaler 
Administrating a drug with a nebulizer attached to a 
positive pressure device is found to be the most effective 
therapy in an individual case 
COPD patients with sleep apnoea are better treated by 
intermittent positive pressure breathing than the regular 
continuous positive pressure treatment of obstructive 
sleep apnoea 
nebulizers in long-term therapy. Patients who benefit from 
nebulizer therapy can be identified only through clinical 
trials. Treatment is considered useful if home PEF values 
improve by over 15% and the patient’s general condition 
improves during 3-6 weeks of therapy. Some patients 
benefit from combined use of a nebulizer and inhalers. 
Intermittent positive pressure breathing (IPPB) means 
respiratory therapy in which the device provides ventilatory 
assistance during inspiration, either automatically or as 
initiated by the patient. Both volume- and pressure- 
controlled ventilators are available. A nebulizer or an 
oxygen flow source can be attached to an IPPB device. 
Using IPPB for drug administration has not clearly been 
shown to be more effective than using nebulizers or inhaler 
therapies. Severe COPD with respiratory insufficiency may 
be treated by nasal intermittent positive pressure ventilation 
(NIPPV) through a nose mask. 
Intermittent positive pressure therapy should be consid- 
ered as domiciliary care only after other treatments alone 
have proven insufficient and additional therapy seems nec- 
essary on the basis of long-term follow-up and acquaint- 
ance with the patient. Indications for domiciliary IPPB and 
nebulizer therapies are shown in Table 30. Before providing 
the patient with the equipment, it has to be assured that the 
patient is able to use, assemble and clean the device and 
administer the drugs. 
Oxygen therapy 
Following development of chronic respiratory failure, 
domiciliary oxygen therapy can improve survival and the 
quality of life of patients. Need for continuous oxygen 
therapy should be assessed during specialized medical care, 
after optimum treatment and intensive rehabilitation. In 
domiciliary oxygen therapy, oxygen should be administered 
for at least 15 h daily if the long-term prognosis is to be 
improved. Criteria for initiation of domiciliary oxygen 
therapy are shown in Table 31. If therapy is started on the 
basis of these criteria, the patient and his or her relatives 
should be prepared for the therapy to be lifelong. 
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TABLE 3i. Criteria for initiation of domiciliary oxygen 
therapy in advanced COPD (FEV, < 1 1) 
Chronic hypoxaemia with PAO, ~7.3 kPa on repeated 
measurement 
Chronic hypoxaemia with PAO, 17.3-7.9 kPa on 
repeated measurement and 
car pulmonale 
polycythaemia (haematocrit >55%) 
marked hypoxaemia on exertion 
neuropsychological symptoms caused by hypoxaemia; 
reversible with oxygen therapy 
significant nocturnal hypoxaemia reversible with oxygen 
therapy and not caused by concomitant sleep apnoea 
Desired response with oxygen therapy (PAO, >8.0 kPa) 
Cessation of smoking by the patient 
Oxygen flow-rates in oxygen systems are determined on 
the basis of arterial blood gas levels. The aim is to raise the 
arterial partial pressure of 0, to over 8 kPa or oxygen 
saturation to over 90%. The oxygen flow rate during 
exertion can be l-2 1 min - i higher than the flow at rest and 
the need for oxygen during sleep may also be greater than 
the basic need. The flow rate to be used should be deter- 
mined carefully in a hospital by monitoring blood oxygen 
and carbon dioxide levels. A continual increase in carbon 
dioxide level should be avoided. If a patient exhibits 
headache or drowsiness in the morning the situation should 
be checked. 
Oxygen systems available for domiciliary oxygen therapy 
include oxygen concentrators, oxygen cylinders and liquid 
oxygen. In Finland, over 90% of patients receiving 
domiciliary oxygen therapy use concentrators. Oxygen con- 
centrators require electricity, and the patient may need a 
reserve of oxygen cylinders for use in, for example, a 
summer cottage. Use of liquid oxygen allows employment 
of relatively light-weight, low-pressure devices that can be 
carried by the patient even when outdoors. Portable oxygen 
containers markedly increase the opportunities of patients 
to participate in social life. All forms of oxygen therapy 
(oxygen concentrators, liquid and pressurized oxygen con- 
tainers) must be prescribed and supervised by the special- 
ized medical care sector, irrespective of who is paying for 
the therapy. The greatest risks in domiciliary oxygen 
therapy relate to fire-safety issues associated with the 
administration and storage of oxygen. Patients’ relatives 
and other care providers should be warned about hazards 
of smoking near oxygen apparatus. 
Patients receiving oxygen therapy often feel tied to the 
apparatus, and withdraw socially. Feelings of fear and lack 
of exercise associated with dyspnoea are central problems in 
such patients. Provision of overall support to the patient is 
an integral part of oxygen therapy. Particular attention 
should be paid to the psychosocial situation. Health-care 
personnel should be readily available. Home visits by a 
rehabilitation instructor or physiotherapist two to three 
times a year help ensure successful home therapy, 
TABLE 32. Indications for hospitalization of patients with 
COPD 
Poor response to outpatient treatment 
Previously ambulatory patient unable to walk 
Patient unable to sleep or eat because of dyspnoea 
Patient unable to cope at home (personal opinion, 
opinion of family or doctor) 
High-risk co-morbid condition (e.g. pneumonia) 
Prolonged symptoms of exacerbation 
Mental changes 
Increased hypoxaemia or hypercapnia 
Development or exacerbation of car pulmonale 
Other aggravating factors (e.g. broken rib or vertebral 
fracture) 
Planned surgery or diagnostic procedure requiring general 
anaesthesia, or medication that will impair pulmonary 
function 
Planned treatment: assessment of the situation, or need 
for respiratory care devices 
increase patients’ feelings of safety and reduce needs for 
hospitalization. 
Hospital tveatmenf 
The onset of an exacerbation of COPD is rarely sudden. In 
most cases, aggravation of the situation is gradual. Dysp- 
noea and mucous secretions increase and sleep is disturbed 
at night. Intensification of treatment in a primary-care ward 
at such a juncture should increase a patient’s trust in the 
heaith-care system, make the patient feel more safe and 
shorten the duration of hospital treatment. In patients 
suffering from repeated exacerbations, a prescheduled treat- 
ment period of l-2 weeks, involving intensification of all 
areas of treatment including physiotherapy, patient educa- 
tion and nutrition, may reduce needs for acute treatment 
and facilitate the overall coping of the family. Indications 
for hospital treatment in COPD are shown in Table 32. 
Table 33 outlines an example of initial treatment of exacer- 
bation of severe COPD. Division of work between primary 
care and specialized medical care wards is described in 
Table 34. 
Swgical treatment 
COPD patients with significant emphysema may have iso- 
lated, large emphysematous bullae. Removal of such bullae 
can sometimes improve a patient’s overall condition and 
lung function. In patients with severe respiratory failure, 
removal of larger emphysematous areas is also possible. 
This promotes the functioning of healthier lung tissue and 
the diaphragm. In isolated cases of severe emphysema, lung 
transplantation may be performed. This applies primarily 
to young patients whose iungs have been destroyed as a 
result of a,-antitrypsin deficiency. 
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TABLE 33. Initial treatment of exacerbation of severe COPD 
Rapid clinical assessment of the overall situation and reassurance of the patient and family 
Oxygen 
Usually l-2 1 min - r through nasal cannulae 
Care should be taken to avoid increase in PACO, at high flow rates 
Nebulizer therapy with 
Sympathomimetic (salbutamol 5510 mg or fenoterol l-2 mg or terbutaline lo-20 mg) plus 
ipratropium 0.5 mg 
Inhaled medication may be repeated after 1 h, subsequently every 3-4 h 
Blood oxygen saturation or PAO, and PACO, measurements 
Chest X-ray and ECG 
Corticosteroids 
Intravenously, preferably as single doses or side infusion 4-6 times a day (hydrocortisone 
200400 mg or methylprednisolone 40-80 mg) 
Prednisolone 30-60 mg or methylprednisolone 24448 mg orally daily 
Theophylline 
Single dose of 100-400 mg administered over lo-20 min in 100 ml of 0.9% saline 
Continuation of infusion at 0.5 mg kg h - r (max. 1000 mg day - ‘) 
Oral theophylline must not be administered during infusion 
Reduced doses in elderly patients and patients with heart or liver disease 
Antibiotics 
Assisted ventilation if necessary 
TABLE 34. Tasks of primary care and specialized medical care in relation to ward therapy 
Primary care Specialized medical care 
Hospital treatment of exacerbations 
Continuation of treatment of severe 
exacerbations 
Prescheduled treatment 
Long-term hospital treatment of 
COPD 
Hospital treatment of severe exacerbations 
Prescheduled treatment 
Assessment of need for respiratory care devices 
Surgical or diagnostic procedures causing temporary 
impairment of breathing 
Hospital treatment in difficult situations among 
patients using respiratory care devices 
Primary health care consultation 
Intensive care 
The results of studies indicate that there is no ethical 
obstacle to consideration of intensive care in any patient 
suffering from COPD, if necessary. Nevertheless, overt very 
poor basic lung function, poor nutritional status, severely 
limited activity and continual decrease of lung capacity may 
warrant abstention from intensive care. However, any 
decision to refrain from intubation and mechanical ventila- 
tion should be based on open discussion between the 
attending physician, patient and patient’s family in 
advance, in a phase in which the patient’s condition is still 
stable. 
Terminal treatment 
Care, moral support and good symptomatic treatment must 
be provided to a patient even after COPD has progressed to 
a stage at which death is inevitable and it is not possible to 
restore the quality of life in accordance with the patient’s 
wishes by any treatment measure. Treatment of fear and 
pain are the primary concerns. The patient must be treated 
through achievement of mutual understanding with the 
patient and his or her family, in accordance with the Act on 
patient care. 
REHABILITATION 
The aims of rehabilitation are to increase patients’ overall 
resources, to reduce handicaps caused by illness or disabil- 
ity in individual patients, and to allow integration in society 
in accordance with an individual’s abilities and age. 
Successful rehabilitation requires initiative and an active 
contribution from both the patient and the body providing 
rehabilitation. Rehabilitation has proved useful in many 
ways, especially when rehabilitation in hospital or other 
TABLE 35. Benefits of pulmonary rehabilitation 
Decrease in respiratory symptoms 
Diminution of feelings of fear and depression and 
improvement of self-esteem 
Increase in ability to deal with daily activities 
Improvement in physical condition 
Improvement in quality of life 
Decrease in number of days in bed 
Prolongation of survival in some patients (oxygen 
therapy) 
institutions has been combined with long-term continual 
rehabilitation at home (Table 35). 
On the basis of the results of the Mini-Suomi study 
conducted by the Social Insurance Institution, it has been 
estimated that there are roughly 100 000 individuals of 
working age whose capacity for work has decreased 
because of chronic bronchitis or COPD. The number 
of disabled individuals is estimated to run to tens of 
thousands. The potential target group for early 
rehabilitation would include 200 000 individuals. 
Medical and social rehabilitation 
According to the Primary Health Care Act (Act 66/72 as 
amended) and the Act on Specialized Medical Care (Act 
1062189) the municipal health-care system bears primary 
responsibility for medical rehabilitation and must provide 
medical rehabilitation as an element in medical care (Decree 
1051191). 
Rehabilitation can be implemented primarily on an out- 
patient basis. Early rehabilitation, which forms an element 
in medical rehabilitation, was discussed in Section 5.3.1. 
However, periodic institutional rehabilitation is necessary, 
particularly in children, in connection with the acquisition 
of respiratory care devices, in patients with severe COPD, 
and in assessing of functional ability and needs for rehabili- 
tation. Forms of medical rehabilitation are listed in 
Table 36. 
TABLE 36. Forms of medical rehabilitation 
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Social rehabilitation forms an integral part of medical 
rehabilitation activities. Social rehabilitation is also pro- 
moted by various group activities, and by adaptation 
training and rehabilitation courses. At present, courses 
directed towards patients with COPD are organized 
primarily for pensioners by the Finnish Slot Machine 
Association, rehabilitation research units in hospitals, and 
various organizations. Short-term courses and outpatient 
services are a!so provided. 
The Social Insurance Institution organizes patient-group- 
specific rehabilitation courses on the basis of an allowance 
ratified in the governmental budget. They are implemented 
primarily in collaboration with rehabilitation institutions 
and organizations as medical rehabilitation of severely 
disabled individuals or rehabilitation based on assessment 
of needs. Outpatient medical rehabilitation of severely 
disabled individuals can also include supported physical 
therapy: as allowed by relevant legislation. Patient associ- 
ations and public-health organizations organize several 
rehabilitation courses annually. The Social Insurance 
Institution pays for the courses at its discretion. 
Occupationally oriented medical rehabilitation is a form 
of early rehabilitation organized by the Social Insurance 
Institution for the population of working age. It aims at 
long-term improvement in and maintenance of capacity for 
work in individuals in whom risk of decreased capacity for 
work is already apparent. ASLAK courses are organized 
for specific vocational groups in the form of national, 
regional or in-company courses. In the case of individuals 
with chronic bronchitis and COPD, it is very important for 
rehabilitation to be focused also on other life-habit-related 
issues in addition to physical activity, such as cessation of 
smoking, nutrition, mental health and respiratory care 
devices. A course of occupationally oriented medical 
rehabilitation directed specifically towards patients with 
respiratory symptoms should be developed. 
Occupational rehabilitation 
Responsibility for occupational rehabilitation is shared 
between many sectors. On the basis of the legislation 
relating to labour services passed on 1 January 1994 it is 
1. Provision of instruction, guidance and support relating to treatment of the disease by the 
health-care system, including instruction regarding use of respiratory care devices, and lending 
and maintenance of such devices 
2. Organization or purchase of adaptation training by hospitals and health centres, and 
therapies and measures to improve functional ability 
3. Implementation of rehabilitation instruction, organized or purchased by the health-care 
system in hospital districts 
4. Interval and periodic rehabilitation in health-care institutions 
5. Support by the Social Insurance Institution of adaptation training and rehabilitation courses 
organized on an outpatient or institutional basis 
6. Organization by the Social Insurance Institution of occupationally oriented medical 
rehabilitation (ASLAK) courses 
7. Outpatient and institutional medical rehabilitation of severely disabled individuals 
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partly the responsibility of work administration. Under the 
Rehabilitation Act, the Social Insurance Institution is 
responsible for organizing the vocational training required 
by patients with chronic bronchitis or COPD whose 
capacity for work and means of earning their livings have 
decreased markedly because of their illnesses, unless such 
training has been organized by virtue of the legislation 
relating to labour services, labour-policy adult vocational 
education or employment pension, or provisions relating to 
special instruction (Act 610191). In practice, vocational 
training organized for patients with COPD on the basis of 
the above-mentioned provisions has been rare, because in 
most patients the disease becomes severe only on the eve of 
their retirement. 
The Social Insurance Institution organizes activities for 
maintaining and improving capacity for work (TYK) in 
elderly individuals. If necessary, the Social Insurance 
Institution can support assessment of needs for rehabilita- 
tion of populations of working age and research into 
rehabilitation.’ 
Under employment pension legislation, employment 
pension agencies can organize occupational rehabilita- 
tion, and medical rehabilitation to support it. Early 
rehabilitation can also be provided. 
A problem with the occupational rehabilitation of 
individuals with chronic bronchitis is that current sets of 
criteria for occupational diseases do not recognize work- 
related chronic bronchitis, although it has also been shown 
in Finnish studies, especially in farmers, that work-related 
exposure plays a role in the development of chronic 
bronchitis. 
SOCIAL SECURITY 
The purpose of social security is to ensure effective treat- 
ment of patients with chronic bronchitis and COPD and the 
livings of individuals and families in the case of incapacity 
for work and disability and costs resulting from treatment 
of illness. General reimbursements prescribed by social 
security legislation include costs of medicines and respirat- 
ory care devices, costs of medical care and rehabilitation, 
daily allowances, disability pensions, and services and 
support provided in the context of welfare of the disabled. 
Legislation relating to occupational diseases ensures 
better social security in cases of illness than other legal 
provisions. The occupational diseases criteria in relation to 
chronic bronchitis and COPD need to be revised. Costs of 
treatment of exacerbations or sick leave caused by work- 
related factors can already be reimbursed in the same way 
as those resulting from occupational diseases. 
The number of individuals with COPD entitled to special 
reimbursement for costs of medicines is estimated as 4500. 
Precise estimation is difficult because patients with asthma 
and COPD have been included in statistics under the same 
heading since 1994. Nevertheless, the figure is clearly too 
low, considering that there are roughly 10 000 patients 
with severe COPD needing repeated hospital treatment 
annually. In practice, the justification for granting special 
reimbursement for the costs of medicines in chronic ob- 
structive airways disease is demonstration that medication 
improves lung-function test results or a decrease in lung 
function to the level of severe disability. The principal aims 
of drug therapy in COPD include elimination of symptoms 
and improvement of the quality of life of the patient, and 
these are not necessarily demonstrable via lung function 
measurements. 
The number of individuals receiving a disability pension 
because of COPD is roughly 2500. In 1992 and 1994, the 
Social Insurance Institution granted rehabilitation allow- 
ances to approximately 90 and 180 COPD patients, respect- 
ively. The corresponding figures for asthma patients were 
3100 and 4000. Numbers of disability pensions and 
rehabilitation allowances are low compared with estimated 
needs (see above). At present, the most important social 
benefits for patients with COPD include rehabilitation 
allowances for the severely disabled and various care allow- 
ances and home and residential services, reflecting defects in 
early diagnosis and early rehabilitation. 
Information, training, research and 
follow-up 
INFORMATION AND TRAINING 
Implementation of the Programme for Chronic Bronchitis 
and Chronic Obstructive Pulmonary Disease will necessi- 
tate training and dissemination of information to key 
groups, and provision of continual guidance. Key groups 
include individuals at high risk of COPD (smokers), those 
who suffer from chronic bronchitis or COPD, those who 
participate directly in treatment and rehabilitation (doctors, 
nurses, rehabilitation personnel), those who can influence 
the nature and extent of exposure (dental-care personnel, 
designers, decision-makers, teachers), those who distribute 
information about matters relating to health and illness 
(journalists, representatives of various organizations, 
the pharmaceutical industry), and those who decide on 
allocation of resources (municipal and governmental 
decision-makers). 
Responsibility for information and training could be 
shared between organizations such as the Allergy and 
Asthma Federation, Folkhalsan (a non-governmental 
health and social organization for the Swedish-speaking 
population in Finland), the Finnish Lung Health 
Association, the Association of the Pulmonary Disabled, 
and the Finnish Indoor Air Association. These could 
distribute information to their members, and to some extent 
to the general public. They also produce suitable material 
for patient education, and health education material relat- 
ing to COPD for schools, in collaboration with health, 
education and environmental authorities. However, these 
activities require financial support from society, e.g. the 
grants from the Finnish Slot Machine Association. 
The Social Insurance Institution plays a key role in 
disseminating information relating to reimbursement of 
costs of medicines, rehabilitation and social security. The 
authorities, in turn, are responsible for dissemination of 
information to professionals and for their training in col- 
laboration with different organizations and associations, 
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TABLE 37. Information and training necessary for implementation of the Programme 
Information and training Time Agent 
Preliminary information and 
information for key groups 
National discussions and training 
National COPD days 
National respiratory care devices days 
Regional training 
Local training 
Spirometer operator training 
Guidance in appropriate use of 
medicines 
General information 
Articles in organizational, professional 
publications 
Provision of material 
Supplementary information and 
training 
1998-2000 
1998-1999 
1997, 1999 etc. 
1998, 2000 etc. 
1998-1999 
1998-2000 
199% Specialized medical care units 
199% Treatment units, pharmacies, the pharmaceutical industry 
1998- 
1998- 
1998-1999 Organizations, authorities and the pharmaceutical industry 
-2007 Authorities and organizations 
Ministry of Social Affairs and Health, Finnish Lung Health 
Association 
Ministry, Finnish Lung Health Association, other 
organizations 
Ministry, organizations, Finnish Association of Specialists in 
Pulmonary Medicine 
Terveydenhuollon Lahipalvelusaatio, organizations 
Hospital districts, provincial governments, Regional 
Institutions for Occupational Health, organizations 
Health centres, occupational health units, pulmonary disease 
units 
Media 
Organizations, experts 
such as the Finnish Association of Specialists in Pulmonary 
Medicine, the Finnish Association of Clinical Physiology, 
the Finnish Association of Municipal Doctors, the Finnish 
Society of Paediatricians, the Finnish Medical Association, 
the Finnish Dental Association, the Finnish Society of 
Internists, the National Union of Public Health Nurses, 
the Union of Health Professionals in Finland and the 
Association of Finnish Pharmacies. Regional direction and 
training are the responsibilities of hospital districts and 
provincial governments. Health centres are in charge of 
local direction and training. The social and health 
authorities bear primary responsibility for implementation 
and follow-up of the Programme. 
The media as a whole, and medical journalists and 
editors in particular, as well as editors of professional 
journals, are in key positions to stimulate discussion on 
the general principles of the Programme and promote 
achievement of its goals. 
Examples of areas of information and training important 
in relation to implementation of the Programme in the near 
future are given in Table 37. 
RESEARCH AND FOLLOW-UP 
In Finland, research into chronic bronchitis and COPD 
has been carried out by universities, the Social Insurance 
Institution, health-care institutions, various organizations, 
the pharmaceutical industry, and individual investigators 
and groups of investigators. 
Few extensive population studies exist on the prevalences 
of the diseases. Those that do exist have helped correct 
estimates relating to prevalences and causes of chronic 
bronchitis and COPD, and their effects on the national 
economy. However, data on incidences, changes in distri- 
bution of degrees of severity, significances of risk factors 
other than smoking, and effects of early diagnosis, early 
rehabilitation and prevention are inadequate. Epidemio- 
logical studies on risk factors relating to COPD and the 
effects of COPD on public health, and intervention studies 
to improve prevention and guided self-care, should be 
intensified, and financial support for such studies secured. 
Studies on preventive measures should form integral parts 
of research into COPD. Multidisciplinary research projects 
should be promoted. Areas of research central to the 
Programme are listed in Table 38. 
Implementation of the Programme will necessitate a 
well-planned, well-functioning and continual quality con- 
trol and direction system. Particular attention should be 
paid to appropriate conduct of lung-function tests, 
TABLE 38. Needs for research and follow-up in relation to 
the Programme for chronic bronchitis and COPD 
Prevalences and incidences of the diseases 
Early diagnosis and treatment 
Environmental factors causing the diseases: descriptions 
and evaluations of risks 
Significance of the environment during the foetal stage 
and infancy 
Indicators of mucosal inflammation 
Impact of rehabilitation on health-care costs 
Creation of extensive systems for follow-up 
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implementation of the programme for the prevention 
of smoking, and assessment of the effects and cost- 
effectiveness of the Programme. 
Existing mortality and hospital discharge records could 
be used to monitor achievement of the overall goals of the 
Programme. Regional models should be developed for 
follow-up of activities in the outpatient care sector. These 
models could be used for sample-based assessments. 
The Ministry of Social Affairs and Health has appointed 
a monitoring group responsible for supporting and evalu- 
ating of the implementation of the National Asthma 
Programme. A similar procedure could be adopted in 
relation to the Programme for the Prevention and 
Treatment of Chronic Bronchitis and COPD. A practicable 
option would be to combine follow-up and support of the 
Programme with the work of the Asthma-Programme 
Monitoring Group that has been appointed or with that of 
the Public-Health Advisory Board. 
Costs of the Programme 
The costs of the Programme for the Prevention and 
Treatment of Chronic Bronchitis and COPD will arise 
mainly from provision of information and training, and the 
system for quality control and direction. However, these 
will not be additional costs but costs relating to normal 
activities of the health-care system and organizations, and 
improvement of such activities. Dissemination of informa- 
tion, training and preparation of materials in relation to the 
launch of the Programme, and to planning of strategies 
(approximately FIM 5 million) should be supported finan- 
cially by, for example, health-promotion grants as set out in 
the Tobacco Act, funds from the Finnish Slot Machine 
Association, and the rehabilitation funds of the Social 
Insurance Institution. The Ministry for Social Affairs and 
Health and the Finnish Slot Machine Association have 
provided grants towards launch of the Programme. 
Apparent additional costs of measures directed towards 
risk groups will be offset by savings in costs arising from 
these and other diseases (e.g. coronary heart disease, lung 
cancer and asthma). 
Implementation of the Programme and improvement of 
quality of prevention and treatment would make it possible 
to treat patients with chronic bronchitis and COPD at 
decreasing costs. If the Programme is not implemented, the 
costs paid by society are bound to rise as severe forms of 
COPD become increasingly prevalent. 
Summary 
1. A national recommendation for the promotion of pre- 
vention, treatment and rehabilitation in relation to 
chronic bronchitis and COPD from 1998 to 2007 has 
been prepared on the basis of extensive collaboration 
by order of the Ministry of Social Affairs and Health. 
The Programme needs to be revised as necessary, 
because of rapid developments in medical knowledge, 
and in drug therapy in particular. 
2. COPD is a disease characterized by slowly progressing, 
irreversible airways obstruction. Over 5% of the popu- 
lation suffer from symptomatic forms of the disease. It 
is estimated that a further 5% of the population may 
suffer from latent COPD. Most patients (75%) suffer 
from mild forms of the disease. The disease is often 
preceded by chronic bronchitis. A total of 400 000 
Finns suffer from chronic bronchitis or COPD. Occur- 
rence of these diseases in future will be particularly 
affected by decreased smoking by men, increased smok- 
ing by the young and by women, and aging of the 
population. 
3. In 1997, the annual treatment costs of chronic bron- 
chitis and COPD were estimated to be FIM 1.5 
thousand million, total costs FIM 5 thousand million. 
Without intensification of measures to prevent and 
treat the diseases, costs will rise significantly. Costs 
arising from severe COPD (5% of patients with COPD) 
account for roughly 65% of costs overall and are 
primarily related to hospitalizations. 
4. The goals of the Programme for the Prevention and 
Treatment of Chronic Bronchitis and COPD are as 
follows: (a) to decrease the incidence of chronic bron- 
chitis; (b) to ensure that as many patients as possible 
with chronic bronchitis recover; (c) to maintain 
capacity for work and functional capacity of patients 
with COPD; (d) to reduce the percentage of patients 
with moderate to severe COPD; (e) to decrease the 
number of hospitalization days of COPD patients by 
25% overall; and (f) to decrease annual costs per 
patient. 
5. The following means are suggested for achieving 
the goals: (a) reduction in smoking; (b) reduction in 
work-related and outdoor air pollutants and improve- 
ment of quality of indoor air; (c) enhancement of 
knowledge about risk factors and treatment of the 
diseases is in key groups; (d) promotion of early 
diagnosis and active treatment, in smokers in particu- 
lar; (e) improvement of guided self-care; (f) early com- 
mencement of rehabilitation, individual planning and 
implementation, primarily as an element in treatment; 
and (g) encouragement of scientific research. 
6. COPD and exacerbation of its symptoms can be pre- 
vented through choices relating to life habits, such as 
not smoking, maintaining good general condition, and 
protection against exposure to dusts. The Programme 
gives examples of such measures and appeals to various 
authorities and voluntary organizations to increase 
their cooperation. Preventive methods should be 
individualized, and based on due consideration. 
7. Chronic bronchitis and COPD should be diagnosed at 
early stages, and treated appropriately from the outset. 
Treatment consists of: (a) treatment according to 
causes, such as stopping smoking and work hygiene; 
(b) early rehabilitation such as patient education 
and guided self-care; (c) drug therapy; (d) hospital 
treatment; and (e) rehabilitation. 
8. The hierarchy of referrals in the treatment of COPD 
should be revised to accord a greater role to the 
primary health care sector. Good exchanges of 
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information and cooperation between the primary 
health care and specialized medical care sectors will all 
be necessary if this hierarchial model is to have the 
desired effect. 
9. Hospital districts and health centres should ensure that 
different levels of the health-care system are capable of 
fulfilling the tasks assigned to them appropriately. One 
specialist in each hospital district should be given 
charge of prevention and assembly of know-how re!at- 
ing to treatment, and of quality of treatment at regional 
level. In the primary health care sector, contact individ- 
uals should be appointed to disseminate information, 
coordinate training and promote cooperation with, for 
example, dental-care personnel. It would be best if 
individuals in charge and acting as contacts were the 
individuals responsible for the National Asthma 
Programme. Prevention and treatment of chronic 
bronchitis and COPD should be matters for regional 
cooperation. 
10. Rehabilitation of patients with chronic bronchitis or 
COPD should cover all forms of rehabilitation: medi- 
cal, occupational and social. Rehabilitation should 
prevent exacerbation of disease, support self-care, 
increase patient resources and improve quality of life, 
reducing needs for hospitalization. Early rehabilitation 
should be increased, and guidance and advice should 
form integral elements in treatment. Rehabilitation 
should be implemented on an outpatient basis as far as 
possible. 
11. Information and training should be directed primarily 
towards key groups, such as patients and their families, 
health-care personnel, and individuals responsible for 
environmental issues. Organizations should dissemi- 
nate information to members and, if necessary, produce 
general material needed for health and patient educa- 
tion relating to chronic bronchitis and COPD, and 
training material, in cooperation with the authorities. 
The Social Insurance Institution should disseminate 
information about reimbursement for medicines 
and social security. The pharmaceutical industry and 
pharmacies will play key roles in supporting infor- 
mation and training. Regional direction and training 
will be the responsibilities of hospital districts, 
provincial governments and local health centres. The 
Ministry of Social Affairs and Health will also be 
responsible for implementation of the Programme, its 
follow-up and, if necessary, its revision. The media 
will play an important role in the dissemination of 
in-depth information about prevention and treatment 
of COPD. 
12. Research should focus on: (a) population studies on 
prevalences of the diseases, risk groups and risk factors; 
and (b) studies aiming at improvement of prevention 
and guided self-care. 
13. If the Programme for the Prevention and Treatment of 
Chronic Bronchitis and COPD for 1998-2007 is imple- 
mented, the increasing numbers of patients who will 
suffer from COPD will be treatable at current costs. 
If not, costs paid by society will increase rapidly. 
Implementation of the Programme will not result in 
significant additional costs. The costs of initiating the 
Programme will be approximately FIM 5 million. 
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Appendix 1 
TABLE Al. Prevalence of chronic bronchitis in different 
areas, by age group and sex 
Place, year 
Age group Men Women 
(years) (%) (%) 
Glamorgan, U.K., 1957 25-74 13.9 8.8 
New Hampshire, U.S.A., 1962 25-75 13.8 9.4 
Tecumseh, U.S.A., 1982 16-64 13.0 4.1 
Uppsala, Sweden, 1968 30-64 2.2 1.5 
Norrbotten, Sweden, 1989 35-66 10.4 7.4 
Busselton, Australia, 1968 20-74 6.3 2.5 
Busselton, Australia, 1985 18-80 21.4 17.2 
Delhi, India, 1977 35-74 12.0 5.0 
Nigeria, 1977 31-70 0.3 0.2 
TABLE A2. Prevalence of COPD in different areas, by age 
group and sex 
Place, year 
Age group Men Women 
(years) (%) (%I 
New Hampshire, U.S.A., 1962 25-75 8.6 8.1 
Tecumseh, U.S.A., 1982 16-64 5.2 2.5 
Copenhagen, Denmark, 1983 40-59 9.5 8.6 
Framingham, U.S.A., 1984 Adult 9.5 6.8 
Busselton, Australia, 1985 18-80 13.5 3.9 
Cracow, Poland, 1986 19-70 8.5 4.9 
Hordaland, Norway, 1988 15-70 5.6 5.2 
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Appendix 2 
NICOTINE DEPENDENCE TEST 
1. How soon after waking up do Less than 6 min 3 
you smoke your first 6-30 min 2 
cigarette? 3 l-60 min 1 
more than 60 min 0 
2. How cigarettes many do you 10 or fewer 0 
smoke daily? 11-20 1 
21-30 2 
more than 30 3 
Total score 
(Fagerstrom Dependence Scale 1997). 
Score 0-l: 
Score 2: 
Score 3: 
Score 446: 
Low dependence. Stopping smoking should 
be fairly easy. 
Moderate dependence. Guidance and nicotine 
replacement therapy by means of transdermal 
patch or 2 mg chewing gum may help with 
stopping smoking. 
High dependence. Guidance and nicotine 
replacement therapy required. Nicotine 
replacement may be implemented using 
transdermal patches, 4 mg chewing gum or 
nasal spray. 
Very high dependence. Stopping smoking 
may be difficult. Long-term support probably 
needed. Nicotine replacement therapy by 
means of 4 mg chewing gum, nasal spray or a 
combination of, e.g. transdermal patch and 
chewing gum. 
Appendix 3 
EXAMPLE OF INTERVENTION BY A DENTIST 
TO PREVENT SMOKING 
At the beginning of a routine school dental examination, 
the dentist asks a pupil whether he or she smokes. The 
following measures are implemented depending on the 
answer. 
1. Pupil does not smoke 
Dental status is examined as usual and the pupil receives 
positive feedback for not smoking. After the examination, a 
series of photographs showing dental staining caused by 
smoking is shown to the pupil. He or she is then allowed to 
check with the help of a mirror whether he or she has 
stained teeth. 
2. Pupil smokes 
Dental status is examined as usual. After the examination, 
a series of photographs showing dental staining caused by 
smoking is shown to the pupil. He or she is then allowed to 
check with the help of a mirror whether he or she has 
stained teeth. 
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Appendix 4 
NICOTINE REPLACEMENT THERAPY 
1. 
2. 
3. 
4. 
5. 
6. 
The efficacy of nicotine replacement therapy can be 
significantly increased by support and follow-up. 
Nicotine chewing gum: treatment should be started 
using a gum strength corresponding to the number of 
cigarettes smoked by the individual and level of nicotine 
dependence. The latter can be assessed by means of the 
Fagerstrom’s Dependence Scale (Appendix 2). A piece 
of gum should be chewed slowly 5-10 times until a 
burning, peppery taste is experienced. The gum should 
then be placed between the teeth and the cheek. The 
taste will disappear after a few minutes. Chewing should 
be repeated and intermittent chewing continued for 
about 30 min. Chewing gum should be used whenever 
there is an urge to smoke, usually lo-15 pieces of gum a 
day. Treatment should be gradually withdrawn after 3 
months of use. Treatment can be stopped when the dose 
is one to two pieces of gum a day. Treatment for more 
than 1 year is not recommended. 
Patch: treatment should be started using a patch 
strength corresponding to the number of cigarettes 
smoked by the individual, applying one patch a day. The 
area of application should be varied daily. The strength 
may be reduced at one-month intervals if necessary. 
Duration of treatment is approximately 2-3 months. In 
individuals with high nicotine dependence, a combina- 
tion of nicotine chewing gum and patch treatment may 
be necessary. 
Nasal spray: used for the treatment of high nicotine 
dependence as directed by a doctor. May be used as 
adjunctive therapy with patches or chewing gum. 
Possible side-effects: nausea, abdominal problems, head- 
ache, sore throat, tenderness of the jaw joints, skin 
reactions at the sites of application of patches, insomnia. 
Irritation of the nasal mucosa in connection with use of 
nasal spray. Abdominal symptoms can be prevented by 
concomitant administration of antacids. 
Contraindications: smoking and temporary smoking. 
Recent myocardial infarction or cereberovascular dis- 
order. Variable or increasing angina and severe 
arrhythmias. Hypersensitivity to nicotine. Caution 
required in individuals under 18 years of age, pregnant 
and lactating women (intake of nicotine should be 
completely avoided). 
7. Interactions: smoking is prohibited during nicotine 
replacement therapy. Stopping smoking also during 
replacement therapy can affect levels and efficacies of 
certain drugs (e.g. theophylline, oestrogen and the 
anticoagulant warfarin). 
Appendix 5 
DIETARY RECOMMENDATIONS TO SUPPORT 
PREVENTION AND TREATMENT OF CHRONIC 
BRONCHITIS AND COPD 
1. Diet should be balanced. 
2. In obese individuals, total dietary energy content should 
be reduced in accordance with desired weight level. The 
energy content of a normal diet aimed at weight 
reduction is 1200-1500 calories a day. 
3. In correcting undernutrition, total energy and proteins 
should be increased. If carbohydrates account for a high 
proportion of total energy effects may be harmful. 
4. Dietary fats should account for no more than 30% of 
total energy (in men, approximately 80 g day - i, in 
women, 60 g day- ‘). Amount of dietary fat can be 
increased in patients with COPD suffering from 
undernutrition. 
5. Saturated fats (i.e. milk fats and other animal fats and 
solid vegetable oils) should not account for more than 
one third of total fat intake (10% of total energy). 
6. Reductions in saturated fats should be compensated for 
by increases in use of mono- and polysunsaturated fats 
(especially fish fat). 
7. Intake of dietary fibre and antioxidants should be 
increased by increasing consumption of vegetables, 
fruits, berries and grain products. 
8. Alcohol consumption should be restricted, in men to no 
more than 2-3 units and in women to l-2 units a day. 
9. Daily salt intake should be below 5 g. 
